<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0139017</article-id>
<article-id pub-id-type="publisher-id">PONE-D-15-21383</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis</article-title>
<alt-title alt-title-type="running-head">Acquired Rifamycin/Isoniazid Resistance</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Rockwood</surname>
<given-names>Neesha</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
<xref rid="cor001" ref-type="corresp">*</xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Abdullahi</surname>
<given-names>Leila H.</given-names>
</name>
<xref rid="aff005" ref-type="aff"><sup>5</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wilkinson</surname>
<given-names>Robert J.</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
<xref rid="aff003" ref-type="aff"><sup>3</sup></xref>
<xref rid="aff004" ref-type="aff"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Meintjes</surname>
<given-names>Graeme</given-names>
</name>
<xref rid="aff001" ref-type="aff"><sup>1</sup></xref>
<xref rid="aff002" ref-type="aff"><sup>2</sup></xref>
<xref rid="aff004" ref-type="aff"><sup>4</sup></xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Medicine, Imperial College, London W2 1PG, United Kingdom</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Clinical Infectious Diseases Research Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Francis Crick Institute Mill Hill Laboratory, London, United Kingdom</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Department of Medicine, University of Cape Town, Cape Town, South Africa</addr-line></aff>
<aff id="aff005"><label>5</label> <addr-line>Vaccines for Africa Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Chatterji</surname>
<given-names>Dipankar</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Indian Institute of Science, INDIA</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: NR GM RJW. Performed the experiments: NR GM. Analyzed the data: NR GM LA. Contributed reagents/materials/analysis tools: NR GM LA. Wrote the paper: NR GM RJW.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">neesha.rockwood@doctors.org.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>25</day>
<month>9</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>10</volume>
<issue>9</issue>
<elocation-id>e0139017</elocation-id>
<history>
<date date-type="received">
<day>18</day>
<month>5</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>9</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-year>2015</copyright-year>
<copyright-holder>Rockwood et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0139017" xlink:type="simple"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>Studies looking at acquired drug resistance (ADR) are diverse with respect to geographical distribution, HIV co-infection rates, retreatment status and programmatic factors such as regimens administered and directly observed therapy. Our objective was to examine and consolidate evidence from clinical studies of the multifactorial aetiology of acquired rifamycin and/or isoniazid resistance within the scope of a single systematic review. This is important to inform policy and identify key areas for further studies.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>Case-control and cohort studies and randomised controlled trials that reported ADR as an outcome during antitubercular treatment regimens including a rifamycin and examined the association of at least 1 risk factor were included. Post hoc, we carried out random effects Mantel-Haenszel weighted meta-analyses of the impact of 2 key risk factors 1) HIV and 2) baseline drug resistance on the binary outcome of ADR. Heterogeneity was assessed used I<sup>2</sup> statistic. As a secondary outcome, we calculated median cumulative incidence of ADR, weighted by the sample size of the studies.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>Meta-analysis of 15 studies showed increased risk of ADR with baseline mono- or polyresistance (RR 4.85 95% CI 3.26 to 7.23, heterogeneity I<sup>2</sup> 58%, 95% CI 26 to 76%). Meta-analysis of 8 studies showed that HIV co-infection was associated with increased risk of ADR (RR 3.02, 95% CI 1.28 to 7.11); there was considerable heterogeneity amongst these studies (I<sup>2</sup> 81%, 95% CI 64 to 90%). Non-adherence, extrapulmonary/disseminated disease and advanced immunosuppression in HIV co-infection were other risk factors noted. The weighted median cumulative incidence of acquired multi drug resistance calculated in 24 studies (assuming whole cohort as denominator, regardless of follow up DST) was 0.1% (5<sup>th</sup> to 95<sup>th</sup> percentile 0.07 to 3.2%).</p>
</sec>
<sec id="sec004">
<title>Conclusion</title>
<p>Baseline drug resistance and HIV co-infection were significant risk factors for ADR. There was a trend of positive association with non-adherence which is likely to contribute to the outcome of ADR. The multifactorial aetiology of ADR in a programmatic setting should be further evaluated via appropriately designed studies.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>Robert J. Wilkinson is supported by the Wellcome Trust <ext-link ext-link-type="uri" xlink:href="http://www.wellcome.ac.uk" xlink:type="simple">www.wellcome.ac.uk</ext-link> [WT 104803; WT084323], UK MRC <ext-link ext-link-type="uri" xlink:href="http://www.mrc.ac.uk" xlink:type="simple">www.mrc.ac.uk</ext-link> [UKMRC U1175.02.002.00014 and MRC-SHIP] and the European Union Grants [EU FP7 HEALTH-F3-2012-305578; FP7-PEOPLE-2011-IRSES], UK MRC [UKMRC U1175.02.002.00014] and the European Union <ext-link ext-link-type="uri" xlink:href="http://ec.europa.eu/" xlink:type="simple">ec.europa.eu</ext-link> [EU FP7 HEALTH-F3-2012-305578; FP7-PEOPLE-2011-IRSES]. Graeme Meintjes was supported by a Wellcome Trust fellowship <ext-link ext-link-type="uri" xlink:href="http://www.wellcome.ac.uk" xlink:type="simple">www.wellcome.ac.uk</ext-link> [WT 098316] and in part by the National Research Foundation (NRF) <ext-link ext-link-type="uri" xlink:href="http://www.nrf.ac.za" xlink:type="simple">www.nrf.ac.za</ext-link> of South Africa [UID: 85858]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="5"/>
<table-count count="5"/>
<page-count count="23"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability" xlink:type="simple">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Resistance to both first line antitubercular drugs rifampicin (of the rifamycin drug class) and isoniazid (multi drug resistant tuberculosis (MDR TB)) is an increasing global health problem. The World Health Organisation (WHO) estimates there were 450,000 cases of MDR TB with 170,000 deaths in 2012 [<xref rid="pone.0139017.ref001" ref-type="bibr">1</xref>]. Cure and completion rates are lower than for drug susceptible TB, with higher mortality rates [<xref rid="pone.0139017.ref002" ref-type="bibr">2</xref>] and there is huge cost to health systems. Whilst transmitted drug resistance has been highlighted as important in fuelling the spread of the epidemic, a better understanding of what factors contribute to the initial emergence of resistance is needed to inform policy. Acquired drug resistance (ADR) is the development, fixation and amplification of mutations conferring resistance under drug pressure during treatment. Verification of true ADR requires ruling out initial dual mixed infection or subsequent exogenous re-infection with a drug resistant strain of <italic>M</italic>. <italic>tuberculosis</italic> (MTB).</p>
<p>ADR has been recognised since chemotherapy was first discovered. The early emergence of ADR with streptomycin monotherapy, heralded the need for multidrug regimens to achieve cure and prevent further accumulation of resistance. The inclusion of rifampicin and pyrazinamide in TB regimens since the 1970s led to shortening of TB regimens from 2 years to 6 months. The rate of stochastic acquired drug resistance has been calculated to be in the order of 2.25 x 10<sup>10</sup> mutations per bacterium per generation for rifampicin and 2.56 x 10<sup>8</sup> mutations per bacterium per generation for isoniazid [<xref rid="pone.0139017.ref003" ref-type="bibr">3</xref>] within the human host. Upon the background of this natural evolution of resistance, programmatic factors such as problems in maintaining drug supplies and ensuring patient adherence and treatment completion have remained and contributed to the global MDR epidemic through creating the selective pressure necessary for ADR to emerge.</p>
<p>A recently published study of ADR in a hollow fibre model system has questioned the conventional notion that poor adherence accounts for the majority of ADR [<xref rid="pone.0139017.ref004" ref-type="bibr">4</xref>]. Several plausible explanations as to how HIV could predispose to ADR have been proposed including malabsorption of antitubercular drugs [<xref rid="pone.0139017.ref005" ref-type="bibr">5</xref>] and host immunosuppression leading to tolerance of strain-specific polymorphisms in the pathway to drug resistance [<xref rid="pone.0139017.ref006" ref-type="bibr">6</xref>]. However, whether HIV is indeed a risk factor for ADR remains to be clarified. The objective of this review was to consolidate evidence from studies that examined any risk factors for acquired rifamycin and/or isoniazid resistance in patients undergoing antitubercular therapy containing a rifamycin at least during the intensive phase. After conducting the systematic review, a post-hoc decision was taken to carry out 2 separate meta-analyses focused on: 1) HIV infection 2) baseline drug resistance as risk factors for the binary outcome of ADR.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Methods</title>
<p>We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We registered the review in PROSPERO (<ext-link ext-link-type="uri" xlink:href="http://crd.york.ac.uk/" xlink:type="simple">crd.york.ac.uk</ext-link> CRD42014003856).</p>
<sec id="sec007">
<title>Selection criteria</title>
<p>We included case-control and cohort studies and randomised controlled trials (RCTs) reporting ADR as either a primary or secondary adverse outcome. To be included, studies had to examine the association of at least 1 risk factor with ADR. Also, patients of any age needed to be on regimens of at least 6 months’ duration which contained rifamycin at least in the intensive phase. We excluded studies that defined ADR as cases of baseline resistance in patients undergoing retreatment for TB. Studies that reported no cases of ADR were excluded. We did not limit our case definition of ADR to studies that had ruled out exogenous re-infection or initial dual mixed infection with different strains using genotypic methods. However, where the data was available, we excluded cases identified as exogenous re-infection via genotyping. Although we collected data on baseline drug sensitivities, the performance of drug sensitivity testing (DST) at baseline in the entire cohort was not required for inclusion. This allowed for inclusion of studies from settings where baseline DST was not routinely performed, but our analyses focussed on those patients in the cohort who did have baseline DST. ADR was defined as identification of new resistance (compared with a baseline isolate of known DST) to rifamycin and/or isoniazid which was made after minimum of 2 weeks on TB treatment or after completion of TB treatment.</p>
</sec>
<sec id="sec008">
<title>Search strategy</title>
<p>Searches were run in Pubmed/MEDLINE, EMBASE, Cochrane Library, Web of Science, Biosis previews and the Trip Database from 1950 to January 2014. In Pubmed, filters were used to select the following languages: Chinese; English; Italian; Russian; Spanish; French. Our keywords were ‘tuberculosis’ or ‘<italic>Mycobacterium tuberculosis’</italic> AND ‘acquired drug resistance’ OR ‘amplified drug resistance.’ We hand-searched reference lists of reviews and eligible papers for other relevant articles in English.</p>
</sec>
<sec id="sec009">
<title>Study selection, data extraction and quality assessment</title>
<p>Two reviewers (NR, GM) independently assessed the titles and abstracts of studies from the searches based on pre-specified eligibility criteria. If it was unclear from the abstract whether inclusion criteria were met, the full article was reviewed. Any uncertainty or disagreement about eligibility was resolved through discussion.</p>
<p>The two reviewers then independently extracted data using a structured data extraction form. Any disagreements were discussed. In cases of missing or incomplete information authors were contacted. Critical appraisal tools, developed in the Critical Appraisal Skills Programme (CASP) for judging methodological quality of RCTs, cohort and case control studies, were amalgamated and used to judge methodological quality [<xref rid="pone.0139017.ref007" ref-type="bibr">7</xref>].</p>
</sec>
<sec id="sec010">
<title>Data synthesis</title>
<p>Risk factors for ADR were tabulated for all studies. If univariate or multivariate analyses were performed, then only if there was a significant association with ADR was the factor categorised as ‘risk factor for ADR’. If no statistical analysis was performed but a risk factor for ADR was described in the study, it was reported as per trend noted. Random effects meta-analyses with Mantel-Haenszel weighting were performed for the covariates baseline drug resistance and HIV co-infection for the binary outcome of ADR using the Cochrane Collaboration Review Manager Version 5.3 statistical software. We calculated risk ratios (RR) and their corresponding 95% confidence intervals (CI) and p-values. Heterogeneity between studies was assessed by calculating the I<sup>2</sup> statistic and its corresponding 95% CI using Stata version 13.1. As a secondary outcome, the cumulative incidence of acquired isoniazid, rifamycin and MDR was reported for individual studies. Patients with known baseline MDR were excluded from calculations. When feasible, the incidence of ADR was calculated using the following denominators: 1) as a proportion of the whole cohort, 2) as a proportion of those with follow up DST, 3) as a proportion of those with baseline pan-susceptibility, 4) as a proportion of those with baseline monoresistance and 5) as a proportion of those with baseline polyresistance. The median cumulative acquired isoniazid, acquired rifamycin and acquired MDR incidence across all studies that reported these was also calculated, weighted by the overall sample size of each study.</p>
</sec>
</sec>
<sec id="sec011" sec-type="results">
<title>Results</title>
<sec id="sec012">
<title>Study selection and assessment</title>
<p>We identified 798 citations through the electronic database searches: 703 were excluded after abstract review. Another 26 studies were identified through reference review. One hundred full text articles were examined and 32 deemed eligible (6 RCTs, 8 prospective cohort, 15 retrospective cohort and 3 case control studies) (<xref rid="pone.0139017.g001" ref-type="fig">Fig 1</xref>).</p>
<fig id="pone.0139017.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Summary of literature search and study selection.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.g001" position="float" xlink:type="simple"/>
</fig>
<p><xref rid="pone.0139017.t001" ref-type="table">Table 1</xref>, <xref rid="pone.0139017.s003" ref-type="supplementary-material">S1</xref> and <xref rid="pone.0139017.s004" ref-type="supplementary-material">S2</xref> Tables provide detailed break down and aggregate data of studies included in the review. Certain studies restricted inclusion to specific populations: those with HIV co-infection (n = 5) [<xref rid="pone.0139017.ref008" ref-type="bibr">8</xref>–<xref rid="pone.0139017.ref010" ref-type="bibr">10</xref>], those incarcerated (n = 1) [<xref rid="pone.0139017.ref011" ref-type="bibr">11</xref>], those with silicotuberculosis (n = 1) [<xref rid="pone.0139017.ref012" ref-type="bibr">12</xref>], those with isoniazid monoresistance (n = 1) [<xref rid="pone.0139017.ref013" ref-type="bibr">13</xref>] and retreatment patients (n = 2) [<xref rid="pone.0139017.ref014" ref-type="bibr">14</xref>–<xref rid="pone.0139017.ref015" ref-type="bibr">15</xref>]. <xref rid="pone.0139017.s005" ref-type="supplementary-material">S3 Table</xref> provides an appraisal of study quality [<xref rid="pone.0139017.ref007" ref-type="bibr">7</xref>]. Loss to follow up was not noted to be significant (pre-defined threshold 20%) in any study. We assessed that in all selected RCTs, treatment effect was measured precisely. We assessed in 20/22 cohort studies, exposure was accurately measured to minimise bias. As illustrated in Tables <xref rid="pone.0139017.t002" ref-type="table">2</xref>–<xref rid="pone.0139017.t005" ref-type="table">5</xref>, only a proportion of individuals included as the ‘whole cohort’ at baseline had follow up DST as per criteria detailed in <xref rid="pone.0139017.s003" ref-type="supplementary-material">S1 Table</xref>. These criteria ranged from being performed at a regular monthly interval in all culture positive isolates; to those who were smear/culture positive at 2 and 5–6 months; to being only performed in cases of suspected failure/relapse. In some cases, this may have compromised accuracy of measurement of outcome.</p>
<table-wrap id="pone.0139017.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of included studies including HIV co-infection, proportion receiving retreatment, treatment regimen, whether treatment was self-administered or directly observed and use of genotyping.</title></caption>
<alternatives>
<graphic id="pone.0139017.t001g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.t001" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Reference</th>
<th align="left" rowspan="1" colspan="1">Study location and year</th>
<th align="left" rowspan="1" colspan="1">HIV prevalence</th>
<th align="left" rowspan="1" colspan="1">Retreatment (ReRx)</th>
<th align="left" rowspan="1" colspan="1">Regimen</th>
<th align="left" rowspan="1" colspan="1">DOT</th>
<th align="left" rowspan="1" colspan="1">Genotyping carried out in a proportion of available isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">RCTs</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Algerian Working Group/British MRC 1991 Tubercle [<xref rid="pone.0139017.ref016" ref-type="bibr">16</xref>]</td>
<td align="left" rowspan="1" colspan="1">Algeria Oct 1981-Dec1983</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">IP: Regimen 1) 2(HRSZ<sub>7</sub>) Regimen 2) 2(HREZ<sub>7</sub>) CP: Regimen 1) 4(HR<sub>7</sub>) Regimen 2) 2(HR<sub>7</sub>)4(H<sub>7</sub>)</td>
<td align="left" rowspan="1" colspan="1">DOT in IP (whilst on streptomycin)</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hong Kong TB Research Centre Madras/BMRC Am Rev Resp Disease 1991 [<xref rid="pone.0139017.ref012" ref-type="bibr">12</xref>]</td>
<td align="left" rowspan="1" colspan="1">Hong Kong Dec 1980–Dec 1985</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">Regimen 1) 6(RHSZ) Regimen 2) 8(RHSZ)<sub>3</sub>(E was added for first 3 months if retreatment patient)</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lienhardt JAMA 2011 [<xref rid="pone.0139017.ref017" ref-type="bibr">17</xref>]</td>
<td align="left" rowspan="1" colspan="1">Algeria, Colombia, Guinea, Vietnam, Peru,Mozambique, Tanzania, Bolivia 2003–2008</td>
<td align="left" rowspan="1" colspan="1">6.6%</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1">IP: Regimen 1) 2(RHEZ<sub>7</sub>) as FDC Regimen 2) 2(RHEZ<sub>7</sub>) as single drugs CP: 4(RH<sub>3</sub>)</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">Yes Spoligo and MIRU-VNTR</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Swaminathan AJRCCM 2010 [<xref rid="pone.0139017.ref010" ref-type="bibr">10</xref>]</td>
<td align="left" rowspan="1" colspan="1">Chenai, India Feb '01–Sep '05</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1">IP: Regimen 1) 2(RHEZ<sub>3</sub>) Regimen 2) 2(RHEZ<sub>3</sub>) CP: Regimen 1) 4(RH<sub>3</sub>) Regimen 2) 7(RH<sub>3</sub>)</td>
<td align="left" rowspan="1" colspan="1">DOT was given during IP. 1/3 doses was given as DOT during CP</td>
<td align="left" rowspan="1" colspan="1">Yes IS6110, MIRU-VNTR, Spoligo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">TB Research Centre IJTLD 1997 [<xref rid="pone.0139017.ref018" ref-type="bibr">18</xref>]</td>
<td align="left" rowspan="1" colspan="1">Chennainot specified</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">IP: Regimen 1) 2(HREZ<sub>7</sub>) Regimen 2) 2(HREZ<sub>2</sub>) Regimen 3) 2(HRZ<sub>2</sub>)CP: Regimen 1) 6(HE<sub>7</sub>) Regimen 2) 4(HRE<sub>2</sub>) Regimen 3) 4(HR<sub>2</sub>)</td>
<td align="left" rowspan="1" colspan="1">Regimen 1 was fully unsupervised. Regimen 2 and 3 were either fully or partially supervised.</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Vernon Lancet 1999 [<xref rid="pone.0139017.ref008" ref-type="bibr">8</xref>]</td>
<td align="left" rowspan="1" colspan="1">USAApr 1995–early 1997</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">47.5%</td>
<td align="left" rowspan="1" colspan="1">IP: 2(RHEZ<sub>7/3/2</sub>) CP: Regimen 1) 4(rifapentine/H<sub>1</sub>) Regimen 2) 4(RH<sub>2</sub>)</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">YesIS6110</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Prospective cohorts</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Aung, IJTLD 2012 [<xref rid="pone.0139017.ref019" ref-type="bibr">19</xref>]<xref rid="t001fn002" ref-type="table-fn">*</xref>operational study with randomisation</td>
<td align="left" rowspan="1" colspan="1">BangladeshJan '06–Jun '07</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1">IP: 2(3) RHEZ<sub>7</sub> CP: 4(HR<sub>3</sub>)</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">Yes Sequencing of core region of <italic>rpoB</italic> gene</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Burman AJRCCM 2006 [<xref rid="pone.0139017.ref009" ref-type="bibr">9</xref>]</td>
<td align="left" rowspan="1" colspan="1">New York City, USA Dec 1998–Mar 2002</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">IP: First 2 weeks: (RHEZ<sub>7</sub>) Next 6 weeks: (RHEZ<sub>5</sub>) or (RHEZ<sub>3</sub>) or (RHEZ<sub>2</sub>) (78% received rifampin in IP) CP: 4-7(RH<sub>2</sub>) R = rifabutin</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">Yes Sequencing of core region of <italic>rpoB</italic> gene</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cox, Clin Infect Dis 2007 [<xref rid="pone.0139017.ref020" ref-type="bibr">20</xref>]</td>
<td align="left" rowspan="1" colspan="1">Karakalpakstan, Uzbekistan and Dashoguz, Turkmenistan Jul 2001–Mar 2002</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">45%</td>
<td align="left" rowspan="1" colspan="1">IP: New 2(HREZ<sub>7</sub>) ReRx 2(SRHEZ7),1(RHEZ<sub>7</sub>) CP: New: 4(HR<sub>3</sub>) ReRx:5(HRE<sub>3</sub>)</td>
<td align="left" rowspan="1" colspan="1">DOT during IP</td>
<td align="left" rowspan="1" colspan="1">Yes RFLP of IS6110 and spoligo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">El Sahly, J of Infect, 2006 [<xref rid="pone.0139017.ref021" ref-type="bibr">21</xref>]</td>
<td align="left" rowspan="1" colspan="1">Houston, USA 1995–2001</td>
<td align="left" rowspan="1" colspan="1">18.1%</td>
<td align="left" rowspan="1" colspan="1">6.3%</td>
<td align="left" rowspan="1" colspan="1"><xref rid="t001fn002" ref-type="table-fn">*</xref>Not specified</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">Yes RFLP of IS6110 and spoligo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Murray SAMJ 2000 [<xref rid="pone.0139017.ref022" ref-type="bibr">22</xref>]</td>
<td align="left" rowspan="1" colspan="1">Goldmines in Gauteng, South Africa, 1995</td>
<td align="left" rowspan="1" colspan="1">49%</td>
<td align="left" rowspan="1" colspan="1">27%</td>
<td align="left" rowspan="1" colspan="1">IP: 2RHZE CP: 4RH</td>
<td align="left" rowspan="1" colspan="1">DOT if smear+</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Nettles, Clin Infect Dis 2004 [<xref rid="pone.0139017.ref023" ref-type="bibr">23</xref>]</td>
<td align="left" rowspan="1" colspan="1">Baltimore, USA Jan '93–Dec '01</td>
<td align="left" rowspan="1" colspan="1">27%</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">IP: 2wks (RHEZ<sub>7</sub>) 6wks (RHEZ<sub>2</sub>) Rifampicin or rifabutin CP: (RHEZ<sub>2</sub>) Rifampicin or rifabutin, duration individualised</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">YesRFLP of IS6110</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Pasipanodya, J Inf Dis 2013 [<xref rid="pone.0139017.ref024" ref-type="bibr">24</xref>]</td>
<td align="left" rowspan="1" colspan="1">Western Cape, South Africa</td>
<td align="left" rowspan="1" colspan="1">10%</td>
<td align="left" rowspan="1" colspan="1">64%</td>
<td align="left" rowspan="1" colspan="1">IP: New 2(HREZ<sub>7</sub>) ReRx 2(SRHEZ7),1(RHEZ<sub>7</sub>) CP: New: 4(HR<sub>3</sub>) ReRx:5(HRE<sub>3</sub>)</td>
<td align="left" rowspan="1" colspan="1">DOT during IP</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Temple Clin Infect Dis 2008 [<xref rid="pone.0139017.ref014" ref-type="bibr">14</xref>]</td>
<td align="left" rowspan="1" colspan="1">Kampala, Uganda Jul 2003–Nov 2006</td>
<td align="left" rowspan="1" colspan="1">48%</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">IP: 1(SRHEZ<sub>7</sub>) 2(RHEZ<sub>7</sub>) CP: 5(RHE<sub>7</sub>)</td>
<td align="left" rowspan="1" colspan="1">DOT in IP (hospitalised)</td>
<td align="left" rowspan="1" colspan="1">Yes RFLP of IS6110</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Retrospective cohorts</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Chien, JAC 2013 [<xref rid="pone.0139017.ref025" ref-type="bibr">25</xref>]</td>
<td align="left" rowspan="1" colspan="1">Taiwan 2005 to 2011</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WHO recommendations IP: New 2(HREZ<sub>7</sub>) ReRx 2(SRHEZ7),1(RHEZ<sub>7</sub>)CP: New 4(HR<sub>3</sub>) ReRx 5(HRE<sub>3</sub>)</td>
<td align="left" rowspan="1" colspan="1">57% received DOTS</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Driver, Clin Infect Dis, 2001 [<xref rid="pone.0139017.ref026" ref-type="bibr">26</xref>]</td>
<td align="left" rowspan="1" colspan="1">New York City Jan 1993–Jun 1996</td>
<td align="left" rowspan="1" colspan="1">33%, (unknown 36%)</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1">IP: Regimen 1) Regimen 2(RHZ<sub>7</sub>) Regimen 2) 2(RHZ<sub>7</sub>) Regimen 3) IP with &lt; 8weeks of Z CP: Regimen 1) 4(RH<sub>7</sub>) Regimen 2) 6(HE<sub>7</sub>) Regimen 3) 7(RH<sub>7</sub>)</td>
<td align="left" rowspan="1" colspan="1">DOT median 21 weeks</td>
<td align="left" rowspan="1" colspan="1">Yes RFLP of IS6110</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Gelmanova, Bull WHO, 2007 [<xref rid="pone.0139017.ref027" ref-type="bibr">27</xref>]</td>
<td align="left" rowspan="1" colspan="1">Tomsk, Siberia Jan 2001–Dec2001</td>
<td align="left" rowspan="1" colspan="1">1%</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WHO recommendations IP: New) 2(HREZ<sub>7</sub>) ReRx): 2(SRHEZ7),1(RHEZ<sub>7</sub>)CP: New: 4(HR<sub>3</sub>) ReRx:5(HRE<sub>3</sub>)</td>
<td align="left" rowspan="1" colspan="1">DOT in inpatient, outpatient and home care setting. Small proportion self-administered therapy</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Jasmer, AJRCCM, 2004 [<xref rid="pone.0139017.ref028" ref-type="bibr">28</xref>]</td>
<td align="left" rowspan="1" colspan="1">San Francisco, United States 1998 to 2000</td>
<td align="left" rowspan="1" colspan="1">13%</td>
<td align="left" rowspan="1" colspan="1">9%</td>
<td align="left" rowspan="1" colspan="1"><xref rid="t001fn002" ref-type="table-fn">*</xref>Not specified</td>
<td align="left" rowspan="1" colspan="1">DOT (n = 149) and SAT (n = 223)</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Kim BMC ID 2008 [<xref rid="pone.0139017.ref013" ref-type="bibr">13</xref>]</td>
<td align="left" rowspan="1" colspan="1">Seoul, Korea Jul 2001–Jun 2005.</td>
<td align="left" rowspan="1" colspan="1">36%</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">IP: 2(RHEZ<sub>7</sub>) CP: 33% 4(REZ<sub>7</sub>) 54% 10(RE<sub>7</sub>) 13% 7(RE<sub>7</sub>)</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Li CID 2005 [<xref rid="pone.0139017.ref029" ref-type="bibr">29</xref>]</td>
<td align="left" rowspan="1" colspan="1">New York City Jan 1997–Dec 2000</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">28%</td>
<td align="left" rowspan="1" colspan="1">IP: Variable rifampin or rifabutin-based regimen, daily or intermittent dose (2/wk or 3/wk) for 2 months CP: rifampin or rifabutin regimen given x2 or 3/wk for 4–6, 7–10 or &gt;10 months</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">YesRFLP of IS6110 and spoligo</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Matthys, PLoS ONE, 2009 [<xref rid="pone.0139017.ref011" ref-type="bibr">11</xref>]</td>
<td align="left" rowspan="1" colspan="1">Mariinsk, Siberia, Russia 1997 to 1998</td>
<td align="left" rowspan="1" colspan="1">None at entry into prison</td>
<td align="left" rowspan="1" colspan="1">65%</td>
<td align="left" rowspan="1" colspan="1">IP: 2(SRHEZ<sub>7</sub>),1(RHEZ<sub>7</sub>) CP: 5(RHE<sub>7</sub>)</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">Yes RFLP of IS6110</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Moulding IJTLD 2004 [<xref rid="pone.0139017.ref030" ref-type="bibr">30</xref>]</td>
<td align="left" rowspan="1" colspan="1">Los Angeles, US Jun 1985–Jul 1992</td>
<td align="left" rowspan="1" colspan="1">Cohort known or presumed to be HIV negative</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">IP: HR and Z or E or ZE (duration and frequency not specified) CP: HR (duration and frequency not specified)</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Porco CID 2012 [<xref rid="pone.0139017.ref031" ref-type="bibr">31</xref>]</td>
<td align="left" rowspan="1" colspan="1">California, USA Jan 1994–Dec 2006</td>
<td align="left" rowspan="1" colspan="1">7.5%</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1"><xref rid="t001fn002" ref-type="table-fn">*</xref>Not specified</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Quy IJTLD 2003 [<xref rid="pone.0139017.ref032" ref-type="bibr">32</xref>]</td>
<td align="left" rowspan="1" colspan="1">Ho Chi Minh City, Vietnam Aug 1996–Jul 1998</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1">IP: New: 2(SHRZ<sub>7</sub>) ReRx 2(SRHEZ<sub>7</sub>),1(RHEZ<sub>7</sub>) CP: New: 6(HE<sub>7</sub>) ReRx:5(HRE<sub>3</sub>)</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">YesRFLP of IS6110</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Seung CID 2004 [<xref rid="pone.0139017.ref033" ref-type="bibr">33</xref>]</td>
<td align="left" rowspan="1" colspan="1">Tomsk, Siberia Nov 1996–Dec 2000</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1">IP: 2(HREZ<sub>7</sub>) In some cases S was given instead of E CP: 4(HR<sub>7</sub>)</td>
<td align="left" rowspan="1" colspan="1">DOT programme IP- hospitalised CP- outpatient</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Spellman 1988 AIDS [<xref rid="pone.0139017.ref034" ref-type="bibr">34</xref>]</td>
<td align="left" rowspan="1" colspan="1">Miami and New York, USA Jan '88–Dec '95</td>
<td align="left" rowspan="1" colspan="1">12.8</td>
<td align="left" rowspan="1" colspan="1">5.2%</td>
<td align="left" rowspan="1" colspan="1"><xref rid="t001fn002" ref-type="table-fn">*</xref>Not specified</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="justify" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Weis, NEJM 1994 [<xref rid="pone.0139017.ref035" ref-type="bibr">35</xref>] #Although presented under cohort studies, this may also be classified as an ecological study</td>
<td align="left" rowspan="1" colspan="1">United States 1980 to 1992</td>
<td align="left" rowspan="1" colspan="1">58 amongst 485 those tested from 1987 (12%)</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">IP: 1980 to 1986 included HRE. 1986 to 1992 included HRZ +/- E or injectable CP: Not specified</td>
<td align="left" rowspan="1" colspan="1">Until 1986 not DOT, from 1986 90.5% received DOT</td>
<td align="justify" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Yoshiyama IJTLD 2004 [<xref rid="pone.0139017.ref015" ref-type="bibr">15</xref>]</td>
<td align="left" rowspan="1" colspan="1">Chiang Rai, Thailand May 1996–Dec 2000</td>
<td align="left" rowspan="1" colspan="1">31%</td>
<td align="left" rowspan="1" colspan="1">100% of re-registered cohort</td>
<td align="left" rowspan="1" colspan="1">IP: 2(SRHEZ<sub>7</sub>),1(RHEZ<sub>7</sub>) CP: 5(RHE<sub>7</sub>)</td>
<td align="left" rowspan="1" colspan="1">DOT introduced in 1996</td>
<td align="left" rowspan="1" colspan="1">Yes RFLP of IS6110</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Yuen, PLoSONE 2013 [<xref rid="pone.0139017.ref036" ref-type="bibr">36</xref>]</td>
<td align="left" rowspan="1" colspan="1">United States2004 to 2011</td>
<td align="left" rowspan="1" colspan="1">Positive 7% Negative 67.5% Unknown 25.5%</td>
<td align="left" rowspan="1" colspan="1">0%</td>
<td align="left" rowspan="1" colspan="1"><xref rid="t001fn002" ref-type="table-fn">*</xref>Not specified</td>
<td align="left" rowspan="1" colspan="1">DOT only 61%, DOT + SAT 37%, SAT only 2%</td>
<td align="justify" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Case controls</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Bradford Lancet 1996 [<xref rid="pone.0139017.ref037" ref-type="bibr">37</xref>]</td>
<td align="left" rowspan="1" colspan="1">San Fransciso, USA Jan '85–Dec '94</td>
<td align="left" rowspan="1" colspan="1">Cases 79% Controls 27%</td>
<td align="left" rowspan="1" colspan="1">Cases 14% Controls 14%</td>
<td align="left" rowspan="1" colspan="1"><xref rid="t001fn002" ref-type="table-fn">*</xref>Not specified</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">Yes RFLP of IS6110</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Munsiff, Clin Infect Dis 1997 [<xref rid="pone.0139017.ref038" ref-type="bibr">38</xref>]</td>
<td align="left" rowspan="1" colspan="1">New York City, USA 93–94</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">IP: Regimen contained RHZ (+/-E), dosing regimen not specified CP: <xref rid="t001fn002" ref-type="table-fn">*</xref>Not specified</td>
<td align="left" rowspan="1" colspan="1">Cases: 24% received DOT Controls: 31% received DOT</td>
<td align="left" rowspan="1" colspan="1">No</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Weiner CID 2005 [<xref rid="pone.0139017.ref039" ref-type="bibr">39</xref>]</td>
<td align="left" rowspan="1" colspan="1">New York City Dec 1998–Mar 2002</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">IP: First 2 weeks: (RHEZ<sub>7</sub>) Next 6 weeks: (RHEZ<sub>5</sub>) or (RHEZ<sub>3</sub>) or (RHEZ<sub>2</sub>) CP: 9(RH<sub>2</sub>)</td>
<td align="left" rowspan="1" colspan="1">100%</td>
<td align="left" rowspan="1" colspan="1">Yes Sequencing of core region of <italic>rpoB</italic> gene</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Abbreviations: IP intensive phase CP continuation phase R rifampin H isoniazid E ethambutol Z pyrazinamide S streptomycin Rx treatment wk week DOT directly observed therapy SAT self-administered therapy X(RHEZ<sub>Y</sub>) X = number of months on regimen y = number of days/week on regimen ARR acquired rifamycin resistance Spoligo Spoligotyping MIRU-VNTR (mycobacterial interspersed repetitive unit-variable- number tandem repeat) typing RFLP of IS6110 restriction fragment length polymorphism of the IS6110 insertion element</p></fn>
<fn id="t001fn002"><p>*individualised treatment as per Centre of Disease Control, USA guidelines <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/mmwr/pdf/rr/rr5211.pdf" xlink:type="simple">http://www.cdc.gov/mmwr/pdf/rr/rr5211.pdf</ext-link>.</p></fn>
<fn id="t001fn003"><p>Whilst treatment regimens were not explicitly stated in 6 (19%) of studies, these all included treatment with a rifamycin during intensive phase and were of minimum 6 months duration.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0139017.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.t002</object-id>
<label>Table 2</label> <caption><title>RCTS- ADR and associated risk factors.</title></caption>
<alternatives>
<graphic id="pone.0139017.t002g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.t002" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Reference</th>
<th align="left" rowspan="1" colspan="1">Cohort description and numbers</th>
<th align="left" rowspan="1" colspan="1">Acquired isoniazid resistance (%)</th>
<th align="left" rowspan="1" colspan="1">Acquired rifamycin resistance (%)</th>
<th align="left" rowspan="1" colspan="1">Acquired MDR TB (%)</th>
<th align="left" rowspan="1" colspan="1">Risk factors associated with acquired drug resistance (ADR)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Algerian Working Group/British MRC 1991 Tubercle [<xref rid="pone.0139017.ref016" ref-type="bibr">16</xref>]</td>
<td align="left" rowspan="1" colspan="1">Whole cohort n = 2218 Known baseline drug sensitivity n = 2071 Follow up drug sensitivity n = 1415</td>
<td align="left" rowspan="1" colspan="1">WC = 1/2071 (0.05) WCFU = 1/1415 (0.07) PS = 1/1376 (0.07) MR<sub>(S)</sub> = 0/40 (0)</td>
<td align="left" rowspan="1" colspan="1">WC = 4/2071 (0.19) WCFU = 4/1415 (0.28) PS = 1/1376 (0.07) MR<sub>(H/S)</sub> = 0/61 (0) PR <sub>(H+S)</sub> = 3/34 (8.8)</td>
<td align="left" rowspan="1" colspan="1">WC = 4/2071 (0.19)WCFU = 4/1415 (0.28) PS = 1/1376 (0.07) MR<sub>(H /S)</sub> = 0/50 PR<sub>(H+S)</sub> = 3/33 (9)</td>
<td align="left" rowspan="1" colspan="1">-Rifampicin in regimen only during intensive phase -Baseline resistance to INH and STREP</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hong Kong TB Research Centre Madras/BMRC Am Rev Resp Disease 1991 [<xref rid="pone.0139017.ref012" ref-type="bibr">12</xref>]</td>
<td align="left" rowspan="1" colspan="1">Whole cohort n = 145 Culture proven TB with known baseline sensitivity n = 127</td>
<td align="left" rowspan="1" colspan="1">WCFU 2/127 (1.6) PS = 2/91 (2.2) MR<sub>(S/R)</sub> = 0/13 (0)</td>
<td align="left" rowspan="1" colspan="1">WCFU 5/127 (3.9) PS 1/91 (1.1) MR<sub>(H/S)</sub> = 1/22 (4.5) PR = 3/9 (33)</td>
<td align="left" rowspan="1" colspan="1">WC = 4/127 (3.1) PS = 1/91 (1.1) MR<sub>(H/S/R)</sub> = 1/25 (4) PR<sub>(H+S)</sub> = 3/9 (33)</td>
<td align="left" rowspan="1" colspan="1">-Baseline drug resistance</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Lienhardt JAMA 2011 [<xref rid="pone.0139017.ref017" ref-type="bibr">17</xref>]</td>
<td align="left" rowspan="1" colspan="1">Culture confirmed smear +ve new TB patients either pan-susceptible or INH monoresistant n = 1170</td>
<td align="left" rowspan="1" colspan="1">WCFU 1/1170 (0.09) PS 1/1005 (0.1)</td>
<td align="left" rowspan="1" colspan="1">WCFU 1/1170 (0.09) PS 0/1005 (0) MR<sub>(H)</sub> 1/127 (0.79)</td>
<td align="left" rowspan="1" colspan="1">WCFU 1/1170 (0.09) PS 0/1005 (0) MR<sub>(H)</sub> 1/127 (0.79)</td>
<td align="left" rowspan="1" colspan="1">-None of the factors analysed were associated (see <xref rid="pone.0139017.s006" ref-type="supplementary-material">S4 Table</xref>)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Swaminathan AJRCCM 2010 [<xref rid="pone.0139017.ref010" ref-type="bibr">10</xref>]</td>
<td align="left" rowspan="1" colspan="1">New TB cases (baseline MDR excluded) n = 327 Culture confirmed with DST and results at end of treatment n = 212</td>
<td align="left" rowspan="1" colspan="1">WC 7/327 (2) WCFU 7/212 (3.3) PS 7/194 (3.6)<xref rid="t002fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">WC 20/327 (6.1) WCFU 20/212 (9.4) PS 11/194 (5.7)<xref rid="t002fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">WC 17/327 (5.2) WCFU 17/212(8.0) PS 11/194 (5.7)<xref rid="t002fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">-Lower median CD4 lymphocyte count (p 0.054)- Higher median HIV VL (p 0.009) -Non-adherence (adherence &lt;90%) (p 0.000) -Baseline isoniazid resistance (OR 8.43, p 0.002)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">TB Research Centre IJTLD 1997 [<xref rid="pone.0139017.ref018" ref-type="bibr">18</xref>]</td>
<td align="left" rowspan="1" colspan="1">Smear +ve TB n = 1203, Followed up post end of treatment and included in relapse analyses n = 777</td>
<td align="left" rowspan="1" colspan="1">WC 22/1053 (2.1) PS 22/825 (2.7) MR<sub>(R)</sub> 1/1 (100)</td>
<td align="left" rowspan="1" colspan="1">WC 26/1053 (2.4) PS 3/825 (0.3) MR<sub>(H)</sub> 23/227 (10)</td>
<td align="left" rowspan="1" colspan="1">WC 26/1053 (2.4) PS 1/825 (0.1) MR<sub>(H/R)</sub> 23/228(10)</td>
<td align="left" rowspan="1" colspan="1">-Lack of ethambutol in a twice weekly regimen -Baseline drug resistance</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Vernon Lancet 1999 [<xref rid="pone.0139017.ref008" ref-type="bibr">8</xref>]</td>
<td align="left" rowspan="1" colspan="1">Culture confirmed drug sensitive TB, HIV co-infected n = 61</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WCFU 4/61 (6.6) PS 4/61 (6.6)<xref rid="t002fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">-Once-weekly isoniazid/rifapentine (p 0.05) Baseline CD4 (p 0.02) -Age (p 0.04) -Extrapulmonary + pulmonary disease (p 0.03)—Use of antifungal azoles (p 0.006)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t002fn001"><p>Abbreviations: WC whole cohort denominator known DST; WCFU denominator f/u DST; PS denominator initial pan-sensitivity; MR denominator initial monoresistance; PR denominator initial polyresistance. H isoniazid S Streptomycin R rifampicin DOT directly observed therapy NTM non-tuberculous mycobacteria MDR multidrug resistant ART antiretroviral therapy BMI body mass index INH isoniazid PZA pyrazinamide.</p></fn>
<fn id="t002fn002"><p><sup>¥</sup>ADR data presented is not stratified by baseline monoresistance and polyresistance as this information cannot be ascertained from the paper.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0139017.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.t003</object-id>
<label>Table 3</label> <caption><title>Prospective cohorts- ADR and associated risk factors.</title></caption>
<alternatives>
<graphic id="pone.0139017.t003g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.t003" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Reference</th>
<th align="left" rowspan="1" colspan="1">Cohort description and numbers</th>
<th align="left" rowspan="1" colspan="1">Acquired isoniazid resistance (%)</th>
<th align="left" rowspan="1" colspan="1">Acquired rifamycin resistance (%)</th>
<th align="left" rowspan="1" colspan="1">Acquired MDR TB (%)</th>
<th align="left" rowspan="1" colspan="1">Risk factors associated with ADR</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Aung, IJTLD 2012 [<xref rid="pone.0139017.ref019" ref-type="bibr">19</xref>] *operational study with randomisation</td>
<td align="left" rowspan="1" colspan="1">Patients who were smear -ve at 2mth and whose IP was not extended n = 12967 Patients who were smear +ve at 2mth and whose IP was extended by 1 mth n = 1871 Patients who were smear +ve at 2mth and whose IP was not extended n = 1870 Smear defined relapses/failures n = 595</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WC 16/16708 (0.09) WCFU 16/595 (2.7)</td>
<td align="left" rowspan="1" colspan="1">WC 12/16708 (0.07) WCFU 12/595 (2)</td>
<td align="left" rowspan="1" colspan="1">None of the factors analysed were associated (see <xref rid="pone.0139017.s006" ref-type="supplementary-material">S4 Table</xref>)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Burman AJRCCM 2006 [<xref rid="pone.0139017.ref009" ref-type="bibr">9</xref>]</td>
<td align="left" rowspan="1" colspan="1">Culture confirmed TB, HIV co-infection and on intermittent rifabutin* based regimen n = 169*78% initially received a median of 33.5 days of rifampin based therapy during IP</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WC = 8/169 (4.7)</td>
<td align="left" rowspan="1" colspan="1">WC = 1/169 (0.59)</td>
<td align="left" rowspan="1" colspan="1">-Lack of use of ART in first 2 months TB treatment (p = 0.05)—Lower CD4 lymphocyte count at diagnosis (p = 0.001)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Cox, Clin Infect Dis 2007 [<xref rid="pone.0139017.ref020" ref-type="bibr">20</xref>]</td>
<td align="left" rowspan="1" colspan="1">Smear +ve TB (baseline MDR patients and mixed infection excluded) n = 314, smear +ve with identical spoligotype as baseline at end of IP or 2 months into CP n = 62</td>
<td align="left" rowspan="1" colspan="1">WCFU 1/314 (0.3) PS 1/177 (0.6) MR<sub>(R/S/Z/E)</sub> 0/51 (0)</td>
<td align="left" rowspan="1" colspan="1">WCFU 11/314 (3.5) PS 1/177 (0.6) MR<sub>(I/S/Z/E)</sub> 0/71 (0) PR<sub>(H+S or I+S+E or I+S+E+Z)</sub> 10/65 (15.3)</td>
<td align="left" rowspan="1" colspan="1">WCFU 11/314 (3.5) PS 1/177 (0.6) MR<sub>(I/S/R/Z/E)</sub> 0/72 (0) PR<sub>(I+S or I+S+E or I+S+E+Z)</sub> 10/65 (15.3)</td>
<td align="left" rowspan="1" colspan="1">-Baseline polyresistance (p&lt;0.05)—Beijing genotype in polyresistant strain (11 out of 28 polyresistant Beijing strains amplified their resistance, compared with none of the 27 non-Beijing strains)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">El Sahly, J Infect, 2006 [<xref rid="pone.0139017.ref021" ref-type="bibr">21</xref>]</td>
<td align="left" rowspan="1" colspan="1">Pan-susceptible TB n = 1977</td>
<td align="left" rowspan="1" colspan="1">PS 9/1977 (0.45)</td>
<td align="left" rowspan="1" colspan="1">PS 7/1977 (0.3)</td>
<td align="left" rowspan="1" colspan="1">PS 1/1977 (0.05)</td>
<td align="left" rowspan="1" colspan="1">-HIV positivity (aOR 5.52 95% CI 1.55–19.68)—Asian ethnicity (aOR 16.74 95% CI 3.8–73.72)—smear positive (aOR 4.76 95% CI 1.42–15.96)—Disseminated TB (with pleural effusion) (aOR 9.22 95% CI 2.82–30.17) aOR adjusted odds ratio</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Murray SAMJ 2000 [<xref rid="pone.0139017.ref022" ref-type="bibr">22</xref>]</td>
<td align="left" rowspan="1" colspan="1">Culture confirmed drug sensitive/monoresistant TB cases (MDR cases excluded) n = 400</td>
<td align="left" rowspan="1" colspan="1">WCFU 6/400 (0.15) PS 6/350 (0.17)<xref rid="t003fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">WCFU 6/400 (0.15) PS 3/350 (0.9) <xref rid="t003fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">WCFU 6/400 (0.5) PS 3/350 (0.9)<xref rid="t003fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">-Baseline drug resistance</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Nettles, Clin Infect Dis 2004 [<xref rid="pone.0139017.ref023" ref-type="bibr">23</xref>]</td>
<td align="left" rowspan="1" colspan="1">Culture confirmed TB (excluding drug resistance, no DOT, alternative regimen, loss to follow up, death) n = 407</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WCFU 3/407 (0.7)</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">-HIV co-infection (p = 0.02) -Lower baseline median CD4 lymphocyte count (p = 0.02)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Pasipanodya, J Inf Dis 2013 [<xref rid="pone.0139017.ref024" ref-type="bibr">24</xref>]</td>
<td align="left" rowspan="1" colspan="1">Smear or culture confirmed drug sensitive TB n = 142</td>
<td align="left" rowspan="1" colspan="1">WCFU 3/142 (2%)</td>
<td align="left" rowspan="1" colspan="1">WCFU 1/142 (0.7%)</td>
<td align="left" rowspan="1" colspan="1">WCFU (0.7%)</td>
<td align="left" rowspan="1" colspan="1">-PK variability including PZA AUC<sub>24</sub> ≤363 mg*h/L, RIF AUC<sub>24</sub>≤13 mg*h/L, and INH AUC<sub>24</sub>≤52mg*h/L</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Temple Clin Inf Dis 2008 [<xref rid="pone.0139017.ref014" ref-type="bibr">14</xref>]</td>
<td align="left" rowspan="1" colspan="1">Smear +ve, culture +ve retreatment TB cases with known DST at baseline admitted to hospital (excluding MDR) n = 269, 5 month follow up sputa n = 237</td>
<td align="left" rowspan="1" colspan="1">WC 2/269 (0.7) WCFU 2/237 (0.8) PS 2/226 (0.9) MR<sub>(S/R)</sub> 0/11 (0)PR<sub>(S+Z/S+E/S+Z+E)</sub> 0/9 (0)</td>
<td align="left" rowspan="1" colspan="1">WC 6/269 (2.2) WCFU 6/237 (2.5) PS 3/226 (1.3) MR<sub>(I/S/Z/E)</sub> 3/38 (10.3) PR<sub>(S+Z/S+E/S+Z+E)</sub> 0/9 (0)</td>
<td align="left" rowspan="1" colspan="1">WC 5/269 (1.9) WCFU 5/237 (2.1) PS 2/226 (0.9) MR 3/31 (9.6) PR 0/9 (0)</td>
<td align="left" rowspan="1" colspan="1">-Baseline resistance (HR 10, p = 0.003)</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>Abbreviations: WC whole cohort denominator known DST; WCFU denominator f/u DST; PS denominator initial pan-sensitivity; MR denominator initial monoresistance; PR denominator initial polyresistance. H isoniazid S Streptomycin R rifampicin E ethambutol Z pyrazinamide, DOT directly observed therapy IP intensive phase CP continuation phase Hb haemoglobin ART antiretroviral therapy BMI body mass index INH isoniazid PZA pyrazinamide RIF rifampin AUC<sub>24</sub> 24 hr area under the concentration-time curve.</p></fn>
<fn id="t003fn002"><p><sup>¥</sup>ADR data presented is not stratified by baseline monoresistance and polyresistance as this information cannot be ascertained from the paper</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0139017.t004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.t004</object-id>
<label>Table 4</label> <caption><title>Retrospective cohorts- ADR and associated risk factors.</title></caption>
<alternatives>
<graphic id="pone.0139017.t004g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.t004" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Reference</th>
<th align="left" rowspan="1" colspan="1">Cohort description and numbers</th>
<th align="left" rowspan="1" colspan="1">Acquired isoniazid resistance (%)</th>
<th align="left" rowspan="1" colspan="1">Acquired rifamycin resistance (%)</th>
<th align="left" rowspan="1" colspan="1">Acquired MDR TB (%)</th>
<th align="left" rowspan="1" colspan="1">Risk factors associated with ADR</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Chien, JAC 2013 [<xref rid="pone.0139017.ref025" ref-type="bibr">25</xref>]</td>
<td align="left" rowspan="1" colspan="1">Culture confirmed pulmonary TB without HIV co-infection (baseline MDR/XDR excluded) n = 2080</td>
<td align="left" rowspan="1" colspan="1">WCFU 108/2080 (5.2)</td>
<td align="left" rowspan="1" colspan="1">WCFU 160/2080 (4.7)</td>
<td align="left" rowspan="1" colspan="1">WCFU 178/2080 (8.6)</td>
<td align="left" rowspan="1" colspan="1">-Age group 45–64 (OR 2.07, p = 0.01) -Smear positivity (OR 2.09, p = 0.01)—Self-administration of treatment/lack of DOT (OR 2.94, p = 0.01)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Driver, Clin Infect Dis, 2001 [<xref rid="pone.0139017.ref026" ref-type="bibr">26</xref>]</td>
<td align="left" rowspan="1" colspan="1">Drug sensitive at baseline n = 4571, Known relapses/recurrences at end of at least 6mths Rx n = 123, Known DST at relapse or recurrence n = 95</td>
<td align="left" rowspan="1" colspan="1">WCFU 14/4571 (0.3) PS 14/4571 (0.3)</td>
<td align="left" rowspan="1" colspan="1">WCFU 21/4571 (0.5) PS 21/4571 (0.5)</td>
<td align="left" rowspan="1" colspan="1">WCFU 9/4571 (0.2) PS 9/4571 (0.2)</td>
<td align="left" rowspan="1" colspan="1">-HIV co-infection (risk factor for acquired RIF monoresistance)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Gelmanova, Bull WHO, 2007 [<xref rid="pone.0139017.ref027" ref-type="bibr">27</xref>]</td>
<td align="left" rowspan="1" colspan="1">Enrolled in DOT n = 260, Culture +ve, with known DST (baseline MDR at excluded) n = 207</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WCFU 15/207 (7.3)</td>
<td align="left" rowspan="1" colspan="1">-Substance abuse (HR 2.88, p = 0.04)-Treatment commenced in hospital setting (HR = 6.34, p = 0.02)—Hospitalisation later in treatment (HR = 6.26, p = 0.047) -Self-administration of Rx/lack of DOT (HR 0.25, p = 0.03)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Jasmer, AJRCCM, 2004 [<xref rid="pone.0139017.ref028" ref-type="bibr">28</xref>]</td>
<td align="left" rowspan="1" colspan="1">Drug sensitive cases of TB who started treatment with allocated DOT status n = 372, Had f/u cultures as part of post-treatment evaluation n = 330</td>
<td align="left" rowspan="1" colspan="1">WC 2/372 (0.5) WCFU 2/330 (0.6) Details of which drugs resistance is acquired to not specified</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">None of the factors analysed were associated (see <xref rid="pone.0139017.s006" ref-type="supplementary-material">S4 Table</xref>)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Kim BMC ID 2008 [<xref rid="pone.0139017.ref013" ref-type="bibr">13</xref>]</td>
<td align="left" rowspan="1" colspan="1">INH resistant at baseline n = 39</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
<td align="left" rowspan="1" colspan="1">WCFU 2/39 (5.1) MR<sub>(H)</sub> 2/39 (5.1%)</td>
<td align="left" rowspan="1" colspan="1">WCFU 2/39 (5.1) MR<sub>(H)</sub> 2/39 (5.1)</td>
<td align="left" rowspan="1" colspan="1">-2 vs 3 drugs in continuation phase -Extensive radiological disease -Smear positivity</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Li CID 2005 [<xref rid="pone.0139017.ref029" ref-type="bibr">29</xref>]</td>
<td align="left" rowspan="1" colspan="1">Confirmed TB with known DST, n = 2861</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WCFU 10/2861 (0.3)</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">-HIV infection aOR, 5.5; 95% CI, 1.4–21.5) Analysis restricted to CD4 count &lt;100: Rifampicin-based (as opposed to rifabutin) regimens aHR 8.5; 95% CI, 1.03–70.9) Analysis restricted to HIV patients on rifampicin-based regimens: patients received intermittent dosing during IP HR 6.4; 95% CI, 1.1–38.44) aOR adjusted odds ratio aHR adjusted hazards ratio</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Matthys, PLoS ONE, 2009 [<xref rid="pone.0139017.ref011" ref-type="bibr">11</xref>]</td>
<td align="left" rowspan="1" colspan="1">Admitted and remained inpatient in penitentiary hospital during treatment (baseline MDR excluded) n = 189</td>
<td align="left" rowspan="1" colspan="1">WCFU 0/189 (0) PS 0/81 (0) MR<sub>(S/R/E)</sub> 0/20</td>
<td align="left" rowspan="1" colspan="1">WCFU 6/189 (3.2) PS 0/81 (0) MR<sub>(H/S/E)</sub> 0/46 (0) PR<sub>(H+E/H+S/H+S+E)</sub> 6/61 (9.8)</td>
<td align="left" rowspan="1" colspan="1">WCFU 6/189 (3.2) PS 0/81 (0) MR<sub>(H/S/R/E)</sub> 0/47 (0) PR<sub>(H+E/H+S/H+S+E)</sub> 6/61 (9.8)</td>
<td align="left" rowspan="1" colspan="1">-Amplification of resistance occurred in 10.7% of those with polyresistance at baseline (vs 3.4% in the whole cohort)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Moulding IJTLD 2004 [<xref rid="pone.0139017.ref030" ref-type="bibr">30</xref>]</td>
<td align="left" rowspan="1" colspan="1">Drug sensitive at baseline n = 5337</td>
<td align="left" rowspan="1" colspan="1">WC 25/5337 (0.47) Details of which drugs resistance is acquired to not specified</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">- Separate drug formulation as opposed to fixed dose combination-Private sector management</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Porco CID 2012 [<xref rid="pone.0139017.ref031" ref-type="bibr">31</xref>]</td>
<td align="left" rowspan="1" colspan="1">Drug sensitive at baseline n = 33725 Repeat DST at follow up n = 1792</td>
<td align="left" rowspan="1" colspan="1">WC 52/33725 (0.15) WCFU 52/1792 (2.9) PS 46/30 548 (0.15) MR<sub>(R)</sub> 6/138 (4.3)</td>
<td align="left" rowspan="1" colspan="1">WC 64/33725 (0.19) WCFU 64/1792 (3.5) PS 37/30 548 (0.1) MR<sub>(I)</sub> 27/3039 (0.9)</td>
<td align="left" rowspan="1" colspan="1">WC 49/33725 (0.1) WCFU 49/1792 (2.7) PS 16/30 548 (0.05) MR<sub>(H/R)</sub> 33/3177 (1)</td>
<td align="left" rowspan="1" colspan="1"><bold>Acquired INH resistance</bold>: -Initial rifampicin resistance (aOR 10.3 p&lt;0.001] -HIV infection (aOR = 3.36, p = 0.01)<bold>Acquired rifampicin resistance</bold>:- Age per year (aOR 0.96, p = 0.002)-HIV infection (aOR = 9.39, p&lt;0.001)-Initial resistance to isoniazid (aOR = 11.2, p&lt;0.001)-Cavitatory disease in the absence of DOT (OR = 2.65, p 0.03) <bold>Acquired MDR:</bold>- Initial isoniazid resistance (aOR = 19.2p&lt;0.001)- Initial rifampicin resistance (aOR = 35.9, p&lt;0.001) -HIV infection (aOR = 5.07, p = 0.003) -Cavitatory disease in the absence of DOT (aOR = 2.65, p = 0.04) aOR = adjusted odds ratio</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Quy IJTLD 2003 [<xref rid="pone.0139017.ref032" ref-type="bibr">32</xref>]</td>
<td align="left" rowspan="1" colspan="1">New smear +ve cases starting TB Rx n = 2901, Culture positive failure and relapse cases with repeat DST and identical ISS610 patterns compared with baseline (baseline MDR excluded)n = 62</td>
<td align="left" rowspan="1" colspan="1">WC 3/2901 (0.1)WCFU 3/62 (4.8)<xref rid="t004fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">WC 18/2901 (0.6) WCFU 17/62 (2.7)<xref rid="t004fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">WC 18/2901 (0.6) WCFU 17/62 (2.7)<xref rid="t004fn002" ref-type="table-fn"><sup>¥</sup></xref></td>
<td align="left" rowspan="1" colspan="1">-Baseline drug resistance (OR 6.6, 95% CI 1.4–32)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Seung CID 2004 [<xref rid="pone.0139017.ref033" ref-type="bibr">33</xref>]</td>
<td align="left" rowspan="1" colspan="1">Enrolled in category 1 treatment regimen n = 2194, Culture positive cases with known DST (baseline MDR cases excluded) n = 1610</td>
<td align="left" rowspan="1" colspan="1">WC 19/1610 (1.2) PS 9/1212 (0.7) MR<sub>(R/E/S)</sub> 6/191 (3.1) PR<sub>(R+E/R+S/R+E+S)</sub> 2/27 (7.4)</td>
<td align="left" rowspan="1" colspan="1">WC 31/1610 (1.9) PS 9/1212 (0.7) MR<sub>(H/E/S)</sub> 6/212 (2.8) PR<sub>(H+S/H+E/H+S+E)</sub> 16/153 (10.4)</td>
<td align="left" rowspan="1" colspan="1">WC 28/1610 (1.7) PS 8/1212 (0.7) MR 6/225 (2.7) PR 18/180 (10)</td>
<td align="left" rowspan="1" colspan="1">-Baseline drug resistance</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Spellman 1988 AIDS [<xref rid="pone.0139017.ref034" ref-type="bibr">34</xref>]</td>
<td align="left" rowspan="1" colspan="1">TB patients with known DST (baseline MDR cases excluded) n = 739</td>
<td align="left" rowspan="1" colspan="1">WC 2/739 (0.3) PS 2/682 (0.3) MR<sub>(S/R/Et)</sub> 0/23 (0) PR<sub>(S+E/S+Et)</sub> 0/5 (0)</td>
<td align="left" rowspan="1" colspan="1">WC 4/739 (0.5) PS 2/682 (0.3) MR<sub>(H/S/Et)</sub> 1/42 (2.4) PR<sub>(H+S/H+E/H+Et/H+Et+S/S+E/S+Et)</sub> 1/14 (7.1)</td>
<td align="left" rowspan="1" colspan="1">WC 2/739 (0.3) PS 2/682 (0.3) MR<sub>(H/S/R/Et)</sub> 1/65 (1.5)PR <sub>H+S/H+E/H+Et/H+Et+S/S+E/S+Et)</sub> 1 /14 (7.1)</td>
<td align="left" rowspan="1" colspan="1">-Baseline drug resistance</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Weis, NEJM 1994 [<xref rid="pone.0139017.ref035" ref-type="bibr">35</xref>]</td>
<td align="left" rowspan="1" colspan="1">Culture confirmed TB (baseline MDR cases excluded), n = 957</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WC 47/957 (4.9)</td>
<td align="left" rowspan="1" colspan="1">-Self-administration of treatment/lack of DOT (p&lt;0.001)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Yoshiyama IJTLD 2004 [<xref rid="pone.0139017.ref015" ref-type="bibr">15</xref>]</td>
<td align="left" rowspan="1" colspan="1">Culture positive cases (baseline MDR cases excluded) n = 1871, patients with repeat DST n = 704 Re-registered cases with DST n = 59</td>
<td align="left" rowspan="1" colspan="1">WC 5/1871 (0.3) WCFU 5/704 (0.7) PS 1/1634 (0.06) MR<sub>(R)</sub> 4/43 (0.09)</td>
<td align="left" rowspan="1" colspan="1">WC 11/1871 ((0.6) WCFU 11/704 (1.6) PS 4/1634 ((0.2) MR<sub>(H)</sub> 7/107 (6.5)</td>
<td align="left" rowspan="1" colspan="1">WC 12/1871 (0.6) WCFU 12/704 ((1.7) PS 1/1634 (0.06) MR<sub>(H/R)</sub> 11/150 (7.3)</td>
<td align="left" rowspan="1" colspan="1">-Previous treatment failure-Baseline resistance—HIV co-infection</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Yuen, PLoSONE 2013 [<xref rid="pone.0139017.ref036" ref-type="bibr">36</xref>]</td>
<td align="left" rowspan="1" colspan="1">Culture confirmed new cases with initial DST n = 51,223, Known genotype and follow up DST (n = 3696 for isoniazid, and n = 4005 for rifamycin)</td>
<td align="left" rowspan="1" colspan="1">WC 61/51223 (0.1) WCFU 61/3696 (1.7)</td>
<td align="left" rowspan="1" colspan="1">WC 50/51223 (0.1)WCFU 50/4005 (1.2)</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1"><bold>Acquired INH resistance</bold> -<italic>M</italic>. <italic>bovis</italic> (aPR = = 8.46, 95% CI 2.96–24.14)<bold>Acquired rifamycin resistance</bold>—<italic>M</italic>. <italic>bovis</italic> (aPR = 4.53, 95% CI 1.29–15.90) -Homeless (aPR = 2.21, 95% CI 1.08–4.52)-HIV co-infection (aPR 8.89, 95% CI 4.43–17.85) -Initial isoniazid resistance (aPR 10.37, 95% CI 5.65–19.00)—Extrapulmonary only disease (aPR 2.31, 95% CI 1.17–4.58) -Self-administered therapy/lack of DOT (aPR 2.52, 95% CI (1.01–6.30) -Initial ethambutol resistance (aPR 4.22, 95% CI (1.06–16.76) -Injecting drug use (aPR 4.09, 95% CI 1.66–10.10) -Age 45–64 (aPR 0.46, 95% CI 0.25–0.85),-Age&gt;65 (aPR 0.14, 95% CI 0.03–0.58) aPR = adjusted prevalence ratio</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t004fn001"><p>Abbreviations: WC whole cohort denominator known DST; WCFU denominator f/u DST; PS denominator initial pan-sensitivity; MR denominator initial monoresistance; PR denominator initial polyresistance.H isoniazid S Streptomycin R rifampicin E ethambutol Et ethioniamide DOT directly observed therapy IP intensive phase CP continuation phase Hb haemoglobin ART antiretroviral therapy BMI body mass index INH isoniazid PZA pyrazinamide R rifampin E ethambutol.</p></fn>
<fn id="t004fn002"><p><sup>¥</sup>ADR data presented is not stratified by baseline monoresistance and polyresistance as this information cannot be ascertained from the paper</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="pone.0139017.t005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.t005</object-id>
<label>Table 5</label> <caption><title>Case-Control studies- ADR and associated risk factors.</title></caption>
<alternatives>
<graphic id="pone.0139017.t005g" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.t005" xlink:type="simple"/>
<table>
<colgroup span="1">
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
<col align="left" valign="middle" span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1">Reference</th>
<th align="left" rowspan="1" colspan="1">Cohort description and numbers</th>
<th align="left" rowspan="1" colspan="1">Acquired isoniazid resistance (%)</th>
<th align="left" rowspan="1" colspan="1">Acquired rifamycin resistance (%)</th>
<th align="left" rowspan="1" colspan="1">Acquired MDR TB (%)</th>
<th align="left" rowspan="1" colspan="1">Risk factors associated with ADR</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Bradford Lancet 1996 [<xref rid="pone.0139017.ref037" ref-type="bibr">37</xref>]</td>
<td align="left" rowspan="1" colspan="1">Total TB cases reported with known DST n = 2612 Cases: acquired resistance to R,H or E with baseline pan-susceptibility n = 14 Control: baseline pan-susceptibility, no ADR, matched to time of diagnosis as cases n = 56</td>
<td align="left" rowspan="1" colspan="1">WC 7/2612 (0.3)</td>
<td align="left" rowspan="1" colspan="1">WC 10/2612 (0.3)</td>
<td align="left" rowspan="1" colspan="1">WC 3/2612 (0.1)</td>
<td align="left" rowspan="1" colspan="1">- White ethnicity (p = 0.015) -Foreign birth (p = 0.007) -Unemployment (p = 0.017)—Self-administration of treatment/lack of DOT (p = 0.045)-ART use (p = 0·014) -Azole use (p&lt;0·001) -GI symtoms (aOR = 11.5, 95%CI = 1.23–107) -Non-adherence (aOR = 19.7, 95%CI = 1.66–234.4) -Baseline AIDS (aOR = 20.2, 95%CI = 1.12–363.6) aOR adjusted odds ratio</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Munsiff, Clin Infect Dis 1997 [<xref rid="pone.0139017.ref038" ref-type="bibr">38</xref>]</td>
<td align="left" rowspan="1" colspan="1">Cases: HIV-TB co-infected patients with confirmed acquired rifamycin monoresistance n = 29 Control: HIV-TB co-infected patients with drug sensitive TB n = 58</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
<td align="left" rowspan="1" colspan="1">N/A</td>
<td align="left" rowspan="1" colspan="1">-Non-adherence (OR 11.0, p&lt;0.001) -Baseline AIDS (OR 5.6, p = 0.005])-Baseline smear positivity (OR = 4.1, p = 0.02)</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Weiner Clin Infect Dis 2005 [<xref rid="pone.0139017.ref039" ref-type="bibr">39</xref>]</td>
<td align="left" rowspan="1" colspan="1">Total in TBTC Study 22 n = 169 Culture confirmed TB, HIV co-infected on intermittent dosing rifabutin regimen who participated in PK sub-study n = 102. Cases of ADR, n = 7. Controls n = 95</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">WC 7/102 (6.9)</td>
<td align="left" rowspan="1" colspan="1">Not specified</td>
<td align="left" rowspan="1" colspan="1">-Lower baseline CD4 lymphocyte count (p = 0.001) -Rifabutin area under curve (AUC<sub>0-24</sub>, p = 0.01) and maximal concentration (p = 0.03)**This association remained, having adjusted for CD4 lymphocyte count</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t005fn001"><p>Abbreviations: WC whole cohort denominator known DST; WCFU denominator f/u DST; PS denominator initial pan-sensitivity; MR denominator initial monoresistance; PR denominator initial polyresistance DOT directly observed therapy IP intensive phase CP continuation phase Hb haemoglobin ART antiretroviral therapy BMI body mass index INH isoniazid PZA pyrazinamide</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec013">
<title>Risk factors associated with ADR</title>
<p>Tables <xref rid="pone.0139017.t002" ref-type="table">2</xref>–<xref rid="pone.0139017.t005" ref-type="table">5</xref> summarise significant associations and trends for ADR. <xref rid="pone.0139017.s006" ref-type="supplementary-material">S4 Table</xref> details all covariates that were examined as potential risk factors.</p>
<p>Studies varied considerably in the potential risk factors examined. The disease burden and pathogen factors most frequently examined were baseline mono and polyresistance (16/32), smear positivity (8/32) and cavitatory disease (7/32). Host immune factors most frequently examined were HIV co-infection (10/32) and CD4 lymphocyte count in HIV-infected patients (8/32). The most frequent sociodemographic covariate examined was age (11/32). The most frequently examined programmatic factor was self-administered therapy (SAT) versus directly observed therapy (DOT) (8/32).</p>
</sec>
<sec id="sec014">
<title>Disease burden and pathogen factors</title>
<p>Baseline drug resistance was positively associated with ADR in 15/16 studies that examined its association. In our meta-analysis of 15 studies (including 45,919 patients), baseline drug resistance (monoresistance or polyresistance) was found to be a significant risk factor for ADR (RR 4.85, 95% CI 3.26 to 7.23), when compared with patients with baseline pan-susceptible MTB (<xref rid="pone.0139017.g002" ref-type="fig">Fig 2</xref>). There was moderate heterogeneity of the data as evidenced by I<sup>2</sup> 58% (95% CI 26 to 76%), the same positive trend was seen in all 15 studies included.</p>
<fig id="pone.0139017.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Forest plot of comparison: 1) baseline drug resistance vs pansusceptible MTB, outcome of ADR: 1.2) ADR by region.</title>
<p>* 1 study was excluded as we were unable to obtain the exact proportion of patients in the study with non-MDR baseline drug resistance and baseline pan-susceptibility either from the paper or by contacting the authors. The endpoint used for the plot for 12 studies was acquisition of isoniazid/rifamycin/multidrug resistance [<xref rid="pone.0139017.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0139017.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0139017.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0139017.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0139017.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0139017.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0139017.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0139017.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0139017.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0139017.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0139017.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0139017.ref033" ref-type="bibr">33</xref>] and the end point for 3 studies was acquisition of rifamycin resistance [<xref rid="pone.0139017.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0139017.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0139017.ref035" ref-type="bibr">35</xref>], based on data available.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.g002" position="float" xlink:type="simple"/>
</fig>
<p>A funnel plot for the meta-analysis of baseline drug resistance as a risk factor for ADR (<xref rid="pone.0139017.g003" ref-type="fig">Fig 3</xref>) showed a dearth of smaller studies reporting negative effects. However, the asymmetry of the funnel plot also appears to be related to substantial heterogeneity among the larger studies with small standard errors, around the summary estimate of effect, with a resulting imbalance toward a large positive effect estimate.</p>
<fig id="pone.0139017.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Funnel plot of studies included in meta-analysis of baseline drug resistance and ADR.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.g003" position="float" xlink:type="simple"/>
</fig>
<p>ADR was significantly associated with extrapulmonary/disseminated TB in 3/5 (60%) studies; with smear positivity in 4/8 (50%) studies; and with extensive radiological disease and cavitatory disease in 1/4 (25%) and 1/7 (14%) studies respectively. <italic>M</italic>. <italic>tuberculosis</italic> complex strain was a risk factor for ADR in 2/4 (50%) studies that examined its role: 1 found increased risk with Beijing strains and 1 with <italic>M</italic>. <italic>bovis</italic>.</p>
</sec>
<sec id="sec015">
<title>Host immunity and PK variability</title>
<p>HIV co-infection was a risk factor for ADR in 8/10 (80%) studies that assessed it. In a meta-analysis of 8/10 studies (35,595 patients), HIV was a significant risk factor for ADR (RR 3.02, 95% CI 1.28 to 7.11) with overall high heterogeneity I<sup>2</sup> 81% (95% CI 64 to 90%) (<xref rid="pone.0139017.g004" ref-type="fig">Fig 4</xref>). Sub-group analysis by continent for ADR showed a RR of 3.23 (95% CI 1.02 to 10.26) with HIV co-infection in 5 North American studies (heterogeneity I<sup>2</sup> 29%, 95% CI 0 to 72%) whilst there was a trend towards a negative association in 2 African studies (RR 0.3, 95% CI 0.07 to 1.19) with heterogeneity I<sup>2</sup> 12%.</p>
<fig id="pone.0139017.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Forest plot of comparison: 1) HIV status, outcome of ADR. 1.2) ADR by region.</title>
<p>Only 8/10 studies which examined HIV as a risk factor for ADR were included as we were unable to obtain the exact proportion of those HIV seropositive among the patients that developed ADR from either the paper or by contacting the authors in the other 2 studies. The end point for 5 studies was acquisition of isoniazid/rifamycin/multidrug resistance [<xref rid="pone.0139017.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0139017.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0139017.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0139017.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0139017.ref033" ref-type="bibr">33</xref>] and the end point for 3 studies was acquisition of rifamycin resistance [<xref rid="pone.0139017.ref022" ref-type="bibr">22</xref>,<xref rid="pone.0139017.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0139017.ref035" ref-type="bibr">35</xref>], based on data available.</p>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.g004" position="float" xlink:type="simple"/>
</fig>
<p>A funnel plot for the meta-analysis of HIV as risk factor of ADR indicated little risk of publication bias (<xref rid="pone.0139017.g005" ref-type="fig">Fig 5</xref>).</p>
<fig id="pone.0139017.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0139017.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Funnel plot of studies included in meta-analysis of HIV and ADR.</title>
</caption>
<graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0139017.g005" position="float" xlink:type="simple"/>
</fig>
<p>A low CD4 lymphocyte count at diagnosis in 5/8 studies (63%) and an AIDS diagnosis in 2/2 studies were significant risk factors for ADR amongst HIV-infected patients. Gastrointestinal symptoms at baseline were associated with ADR in 1/1 study and concurrent use of antifungal azoles in 2/2 studies. PK variability was found to be a risk factor for ADR in both studies examining its role. Weiner <italic>et al</italic> found that a lower area under the curve (AUC<sub>0-24hr</sub>) and lower peak concentration (C<sub>max</sub>) for rifabutin was associated with increased risk of ADR. This was in a sub-cohort of patients who were sampled during continuation phase therapy. There was no significant difference in isoniazid C<sub>max</sub> or AUC<sub>0-24hr</sub> in cases of ADR, compared with controls. Pasipanodya <italic>et al</italic> found that low rifampicin and isoniazid peak concentrations and AUC<sub>0-24hr</sub> preceded ADR in 3 patients.</p>
</sec>
<sec id="sec016">
<title>Sociodemographic factors</title>
<p>Older age [4/11(36%)], foreign birth [1/3 (33%)], ethnicity [2/5 (40%)], unemployment [1/1], substance abuse [2/4 (50%)] and homelessness [1/3 (33%)] were found to be risk factors for ADR in certain studies.</p>
</sec>
<sec id="sec017">
<title>TB regimen and adherence</title>
<p>Non-adherence was assessed as a risk factor for ADR in 5/32 studies and was associated with ADR in 3/5 (60%) of studies. Directly observed therapy was a risk factor for ADR in 1/8 (12.5%) studies that compared the practice of SAT with DOT. In contrast, SAT was found to be a risk factor for ADR in 4/8 (50%) studies. There was no association between DOT or SAT and ADR in 3 studies. Separate drug formulation, as opposed to fixed dose combination (FDC), was found to be a risk factor for ADR in 1/3 (33%) of studies. Use of rifampicin in the regimen only during intensive phase [<xref rid="pone.0139017.ref016" ref-type="bibr">16</xref>] and lack of ethambutol [<xref rid="pone.0139017.ref018" ref-type="bibr">18</xref>] in a twice/once weekly dosing regimen were associated with cases of ADR in individual RCTs carried out in the 1990s. In one retrospective cohort study, in a sub-analysis of HIV co-infected patients, intermittent dosing of rifampicin during the intensive phase and use of rifampicin instead of rifabutin was associated with ADR [<xref rid="pone.0139017.ref029" ref-type="bibr">29</xref>]. This was in contrast to sub-analysis of HIV-infected patients in another study where there was no significant difference in ADR comparing rifampicin and rifabutin-based regimens [<xref rid="pone.0139017.ref023" ref-type="bibr">23</xref>]. In a RCT, a once weekly rifapentine based regimen in continuation phase was associated with ADR in HIV co-infected individuals [<xref rid="pone.0139017.ref009" ref-type="bibr">9</xref>].</p>
</sec>
<sec id="sec018">
<title>Cumulative incidence of ADR</title>
<p>Tables <xref rid="pone.0139017.t002" ref-type="table">2</xref>–<xref rid="pone.0139017.t005" ref-type="table">5</xref> report DST data and cumulative incidence of acquired isoniazid, rifamycin and MDR for individuals studies stratified by whole cohort, whole cohort with follow up DST, baseline pan-susceptibility, baseline mono-resistance and baseline poly-resistance. In 25 studies, which reported acquired MDR, when considering the overall cohort as denominator, the weighted median incidence of acquired MDR was 0.1% (5<sup>th</sup> to 95<sup>th</sup> percentile 0.07 to 3.2%). In 20 studies reporting acquired isoniazid resistance, when considering the overall cohort as denominator, the weighted median incidence of acquired isoniazid resistance was 0.1% (5<sup>th</sup> to 95<sup>th</sup> percentile 0.1 to 0.7%). In the 27 studies reporting acquired rifamycin resistance, when considering the overall cohort as denominator, the weighted median incidence of acquired rifamycin resistance was 0.1% (5<sup>th</sup> to 95<sup>th</sup> percentile 0.09 to 0.7%). In patients with baseline pan-susceptibility (data available in 15 studies) the weighted median incidence of acquired MDR was 0.2% (5<sup>th</sup> to 95<sup>th</sup> percentile 0 to 0.9%). In those with baseline pan-susceptibility, acquired isoniazid resistance (weighted median incidence 0.3%, 5<sup>th</sup> to 95<sup>th</sup> percentile 0.06 to 2.7%) did not appear to be more frequent than acquired rifamycin resistance (weighted median incidence 0.3%, 5<sup>th</sup> to 95<sup>th</sup> percentile 0 to 0.9%). The weighted median incidence of acquired MDR in patients with baseline monoresistance (data available in 12 studies) was 1% (5<sup>th</sup> to 95<sup>th</sup> percentile 0.79 to 10%). The weighted median incidence of acquired MDR in patients with baseline polyresistance (data available in 7 studies) was 10% (5<sup>th</sup> to 95<sup>th</sup> percentile 7.1 to 15.5%). It must be noted, that the above estimates of incidence of ADR refer only to studies included in this review and with our search strategy, we excluded studies in which no cases of ADR occurred.</p>
</sec>
</sec>
<sec id="sec019" sec-type="conclusions">
<title>Discussion</title>
<p>Although acquired MDR was rare overall [weighted median frequency 0.1%], it was more frequent in certain risk groups such as those with baseline mono or polyresistance. A meta-analysis of 15 studies with a moderately heterogeneous data set showed a RR for ADR of 4.96 in patients with baseline drug resistance compared with baseline pan-susceptible profiles. Studies reporting ADR as a treatment outcome varied in geographical location, HIV co-infection, retreatment proportions and treatment regimens administered during intensive and continuation phase as summarised in <xref rid="pone.0139017.t001" ref-type="table">Table 1</xref> and <xref rid="pone.0139017.s004" ref-type="supplementary-material">S2 Table</xref>. Weighted pooled analysis of a highly heterogeneous data set showed an increased risk of ADR (RR 3.02) with HIV co-infection. The data presented disaggregated by continent showed a significant association with HIV co-infection in 5 North American studies whilst there was a trend towards a negative association in 2 African studies. This negative association of HIV with ADR in Africa, may partly be explained by a relatively higher proportion of HIV infected patients who develop ADR dying prior to the detection of ADR. Advanced immunosuppression as reflected by a lower baseline CD4 lymphocyte count or AIDS at diagnosis was a risk factor in HIV co-infected patients. Poor adherence and extrapulmonary/disseminated disease were risk factors for ADR in 60% of studies. There was less conclusive evidence regarding the role of PK variability, strain type, DOT versus self-administered therapy, fixed dose combinations and choice of rifamycin as risk factors.</p>
<p>The wide range in reported incidence of ADR may be partially explained by lack of standardization in reporting. For example, where follow up culture and DST results are missing, either the denominator can be altered to reflect this, or the denominator remains as the original cohort number; the assumption being that those with missing DST did not develop ADR. In this review we have presented cumulative incidence of ADR in individual studies, for both the whole cohort and limited to those with follow up DST data.</p>
<p>Baseline mono or polyresistance has previously been recognised as a significant risk factor for ADR. Lew <italic>et al</italic> [<xref rid="pone.0139017.ref040" ref-type="bibr">40</xref>] carried out a meta-analysis looking at the role of initial drug resistance on TB treatment outcomes. Of note, many studies carried out in the 1970s only used rifamycins during a 2 month intensive phase. Lew <italic>et al</italic> found that the cumulative incidence of ADR increased from 0.8% (95% CI 0.5 to 1%) in baseline pan-susceptible cases to 6% (95% CI 4 to 8%) in baseline monoresistant cases and 14% (95% CI 9 to 20%) in baseline polyresistant cases [<xref rid="pone.0139017.ref040" ref-type="bibr">40</xref>]. A review by Menzies <italic>et al</italic> [<xref rid="pone.0139017.ref041" ref-type="bibr">41</xref>] found that in patients with baseline isoniazid monoresistance, a longer duration of rifampicin, use of streptomycin, daily therapy initially, and treatment with a greater number of effective drugs were associated with reduced risk of ADR. Jacobsen <italic>et al</italic> reported 9% progression to MDR TB in a cohort with baseline isoniazid monoresistance who received 12 months of quadruple therapy [<xref rid="pone.0139017.ref042" ref-type="bibr">42</xref>]. In many resource limited settings, Xpert MTB/RIF is used to test for baseline rifampicin resistance and baseline isoniazid resistance will go undetected. During continuation phase, those with isoniazid monoresistance (particularly high level) who are still culture positive, will be effectively receiving rifampicin monotherapy. Hence, there is potential for amplification of drug resistance.</p>
<p>The role of HIV co-infection in the acquisition of TB drug resistance has been a topic of debate. In an immunocompromised host, there is an increased risk of disseminated TB; the latter being an independent risk factor for ADR. Hence, there may be an increased bacterial burden leading to an increased probability of bacteria undergoing spontaneous mutation. It is also hypothesized that less fit drug resistant strains survive longer in the context of poor immunity, allowing for development of compensatory mutations to restore fitness [<xref rid="pone.0139017.ref043" ref-type="bibr">43</xref>–<xref rid="pone.0139017.ref045" ref-type="bibr">45</xref>]. Some MTB strain types are particularly prevalent in immunocompromised hosts [<xref rid="pone.0139017.ref045" ref-type="bibr">45</xref>]. HIV co-infection may cause changes in gut permeability leading to malabsorption of antituberculous drugs [<xref rid="pone.0139017.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0139017.ref046" ref-type="bibr">46</xref>]. As antiretroviral therapy (ART) becomes increasingly available and guidelines advocate early commencement of ART, it remains to be seen if HIV co-infection will continue to be associated with ADR.</p>
<p><italic>In vitro</italic> work in hollow fibre models has suggested that PK variability and inadequate dosing of TB drugs may be an important risk factor for ADR [<xref rid="pone.0139017.ref047" ref-type="bibr">47</xref>,<xref rid="pone.0139017.ref048" ref-type="bibr">48</xref>]. This is supported by findings from cohort studies [<xref rid="pone.0139017.ref024" ref-type="bibr">24</xref>,<xref rid="pone.0139017.ref039" ref-type="bibr">39</xref>]. However, these results need to be confirmed in studies with robust determination of PK indices and appropriate controls. Pasipanodya <italic>et al</italic> [<xref rid="pone.0139017.ref049" ref-type="bibr">49</xref>] reviewed the role of N-acetyl-transferase type 2 genotype in acquired isoniazid resistance. The link they found between slow acetylator status and ADR may be less significant in the context of currently utilised rifampicin-containing multidrug regimens.</p>
<p>Two studies showed an association with MTB strain. Cox <italic>et al</italic> found an association between Beijing strain and ADR [<xref rid="pone.0139017.ref020" ref-type="bibr">20</xref>]. In a database of 3696 MTB complex strains, 72% of which were Euro-American lineage, only <italic>M</italic>. <italic>bovis</italic> was associated with ADR [<xref rid="pone.0139017.ref036" ref-type="bibr">36</xref>]. Luria-Delbrück fluctuation analyses have suggested that MTB lineage 2 (Beijing) strains are associated with increased mutation rates and acquisition of drug resistance [<xref rid="pone.0139017.ref050" ref-type="bibr">50</xref>]. This may potentially be through sign epistasis where there is favourable interaction between drug resistance mutations and genetic background of the strain [<xref rid="pone.0139017.ref051" ref-type="bibr">51</xref>].</p>
<p>There is no standardized means of measuring adherence and the measure chosen depends on the setting, burden of disease, infrastructure and resources available. Whilst some studies have used DOT (as opposed to SAT), as a surrogate measure of adherence, we have not made this assumption as the outcome of DOT may be confounded by its indication. We have examined non-adherence as a separate risk factor to DOT versus SAT. Non-adherence was a significant risk factor in 3/5 [<xref rid="pone.0139017.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0139017.ref036" ref-type="bibr">36</xref>,<xref rid="pone.0139017.ref037" ref-type="bibr">37</xref>] of the studies that examined its association with ADR. For the 2 studies which showed no significant association between non-adherence and ADR, there was a trend of positive association for 1 of the studies [<xref rid="pone.0139017.ref026" ref-type="bibr">26</xref>] but in the other, all 5 cases of ADR were noted to be adherent with therapy. The impact of DOT versus SAT on ADR was less clear with a protective effect of DOT seen in 50% of studies. A meta-analysis by Pasipanodya <italic>et al</italic> showed no increased risk of microbiologic failure, relapse, or ADR with DOT compared with SAT [<xref rid="pone.0139017.ref052" ref-type="bibr">52</xref>]. Intermittent dosing frequency has been linked with adverse outcomes, including ADR, when administered during intensive phase [<xref rid="pone.0139017.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0139017.ref029" ref-type="bibr">29</xref>], particularly in the context of HIV co-infection.</p>
<p>There are several limitations to this review. The primary focus of the review was evaluating risk factors for ADR. It is not possible to gather any meaningful data regarding risk factors for an event from a study in which no events are reported and consequently, studies that either reported ADR but no risk factors or 0% ADR were excluded and this potentially affected the estimates of ADR cumulative incidence, which was a secondary analysis. There was incomplete MTB strain genotyping to rule out the possibility of dual mixed infection or exogenous re-infection. Only 47% of studies confirmed ADR with identical MTB genotype at baseline and follow-up. Even where genotyping was part of the study design, in some, a proportion of suspected ADR isolates were not available for genotyping [<xref rid="pone.0139017.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0139017.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0139017.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0139017.ref028" ref-type="bibr">28</xref>]. Many studies were retrospective and had small sample sizes and missing DST. Hence, some studies were likely to have been underpowered and there may have been misclassification bias. There were no statistical analyses of risk factors for ADR in 13 studies because the primary outcome was not ADR. We were limited to noting trends of risk for ADR in the studies. We only conducted meta-analyses of HIV co-infection and baseline drug resistance as risk factors. For the meta-analyses undertaken, the weighted estimates of effect size, must be taken in context of moderate to high heterogeneity in the random effects model [<xref rid="pone.0139017.ref053" ref-type="bibr">53</xref>,<xref rid="pone.0139017.ref054" ref-type="bibr">54</xref>]. This heterogeneity is not surprising, considering different geographical populations, varying MTB strains, different regimens and dosing frequencies, different programmatic factors such as self-administered vs DOT and different proportions of retreatment vs new patients. There were also differences in study methodology such as choice of denominator in the calculation of cumulative incidence of ADR and lack of confirmatory genotyping in all studies.</p>
<p>Previous reviews have focussed on a specific risk factor such as fixed dose combination vs. separate drug formulation [<xref rid="pone.0139017.ref055" ref-type="bibr">55</xref>], duration and dosing frequency of rifamycin [<xref rid="pone.0139017.ref056" ref-type="bibr">56</xref>] and baseline isoniazid monoresistance[<xref rid="pone.0139017.ref040" ref-type="bibr">40</xref>]. The strength of this review is that it consolidates the multifactorial aetiology of ADR within a single systematic review.</p>
<p>In conclusion, baseline drug resistance and HIV co-infection were significant risk factors for ADR. Overall, there were limitations of the current evidence and difficulties in evaluating possible contributors to ADR with heterogeneity secondary to both clinical and/or methodological diversity. Although the data are variable, disseminated disease and non-adherence had positive trends of association for ADR. There are likely many other variables contributing to acquired rifamycin and/or isoniazid resistance and studies to date have not adequately evaluated factors such as PK variability and MTB strain type as risk factors for ADR. The multifactorial aetiology ADR in a programmatic setting should be further evaluated via appropriately designed studies.</p>
</sec>
<sec id="sec020">
<title>Supporting Information</title>
<supplementary-material id="pone.0139017.s001" xlink:href="info:doi/10.1371/journal.pone.0139017.s001" mimetype="application/msword" position="float" xlink:type="simple">
<label>S1 PRISMA Checklist</label>
<caption>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0139017.s002" xlink:href="info:doi/10.1371/journal.pone.0139017.s002" position="float" xlink:type="simple">
<label>S1 File</label>
<caption>
<title>RevMan data.</title>
<p>(RM5)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0139017.s003" xlink:href="info:doi/10.1371/journal.pone.0139017.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:type="simple">
<label>S1 Table</label>
<caption>
<title>Characteristics of included studies including location and year, criteria for repeat DST and technique used.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0139017.s004" xlink:href="info:doi/10.1371/journal.pone.0139017.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:type="simple">
<label>S2 Table</label>
<caption>
<title>Aggregate data of studies included in the review.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0139017.s005" xlink:href="info:doi/10.1371/journal.pone.0139017.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:type="simple">
<label>S3 Table</label>
<caption>
<title>Study quality based on criteria developed in the Critical Appraisal Skills Programme.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0139017.s006" xlink:href="info:doi/10.1371/journal.pone.0139017.s006" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:type="simple">
<label>S4 Table</label>
<caption>
<title>Risk factors for acquired drug resistance examined.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>The authors thank Vittoria Lutje, information retrieval specialist at the Cochrane Infectious Diseases Group, Liverpool, for assistance with carrying out the literature searches, Taryn Young, Centre for Evidence-based Health Care, Stellenbosch University, for methodological guidance, Michael Schomaker, School of Public Health and Family Medicine, University of Cape Town for methodological guidance and Mark Engel, Evidence-Based Medicine Research Support Unit, University of Cape Town for methodological guidance and assistance with designing figures.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0139017.ref001"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organisation. Multidrug-resistant tuberculosis (MDR-TB) 2013 Update. 2013. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/tb/challenges/mdr/en/" xlink:type="simple">http://www.who.int/tb/challenges/mdr/en/</ext-link>. Updated 2013. Accessed January/20, 2015.</mixed-citation></ref>
<ref id="pone.0139017.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gandhi</surname> <given-names>NR</given-names></name>, <name name-style="western"><surname>Nunn</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Dheda</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Schaaf</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Zignol</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>van Soolingen</surname> <given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>(<issue>9728</issue>):<fpage>1830</fpage>–<lpage>43</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(10)60410-2" xlink:type="simple">10.1016/S0140-6736(10)60410-2</ext-link></comment> <object-id pub-id-type="pmid">20488523</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>David</surname> <given-names>HL</given-names></name>. <article-title>Probability distribution of drug-resistant mutants in unselected populations of <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Appl. Microbiol.</source><year>1970</year> <volume>20</volume>:<fpage>810</fpage>–<lpage>814</lpage>. <object-id pub-id-type="pmid">4991927</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Srivastava</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pasipanodya</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Meek</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Leff</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Gumbo</surname> <given-names>T</given-names></name>. <article-title>Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability</article-title>. <source>J Infect Dis</source> <year>2011</year>;<volume>204</volume>(<issue>12</issue>):<fpage>1951</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jir658" xlink:type="simple">10.1093/infdis/jir658</ext-link></comment> <object-id pub-id-type="pmid">22021624</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peloquin</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Berning</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Huitt</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Iseman</surname> <given-names>MD</given-names></name>. <article-title>AIDS and TB drug absorption</article-title>. <source>Int J Tuberc Lung Dis</source> <year>1999</year>;<volume>3</volume>(<issue>12</issue>):<fpage>1143</fpage>–<lpage>4</lpage>. <object-id pub-id-type="pmid">10599022</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Muller</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Borrell</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Rose</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Gagneux</surname> <given-names>S</given-names></name>. <article-title>The heterogeneous evolution of multidrug-resistant <italic>Mycobacterium tuberculosis</italic>. <italic>Trends Genet</italic></article-title>: <source>TIG</source>. <year>2013</year>;<volume>29</volume>(<issue>3</issue>):<fpage>160</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.tig.2012.11.005" xlink:type="simple">10.1016/j.tig.2012.11.005</ext-link></comment> <object-id pub-id-type="pmid">23245857</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref007"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Critical Appraisal Skills Programme. <ext-link ext-link-type="uri" xlink:href="http://www.sph.nhs.uk/what-we-do/public-healthworkforce/" xlink:type="simple">http://www.sph.nhs.uk/what-we-do/public-healthworkforce/</ext-link></mixed-citation></ref>
<ref id="pone.0139017.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Vernon</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Burman</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Benator</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Bozeman</surname> <given-names>L</given-names></name>. <article-title>Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium</article-title>. <source>Lancet</source>. <year>1999</year>;<volume>353</volume>(<issue>9167</issue>):<fpage>1843</fpage>–<lpage>7</lpage>. <object-id pub-id-type="pmid">10359410</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Burman</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Benator</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Vernon</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Jones</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Silva</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2006</year>;<volume>173</volume>(<issue>3</issue>):<fpage>350</fpage>–<lpage>6</lpage>. <object-id pub-id-type="pmid">16109981</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Swaminathan</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Narendran</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Venkatesan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Iliayas</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Santhanakrishnan</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Menon</surname> <given-names>PA</given-names></name>, <etal>et al</etal>. <article-title>Efficacy of a 6-month versus 9-month Intermittent Treatment Regimen in HIV-infected Patients with Tuberculosis A Randomized Clinical Trial</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2010</year>;<volume>181</volume>(<issue>7</issue>):<fpage>743</fpage>–<lpage>51</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1164/rccm.200903-0439OC" xlink:type="simple">10.1164/rccm.200903-0439OC</ext-link></comment> <object-id pub-id-type="pmid">19965813</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Matthys</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Rigouts</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Sizaire</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Vezhnina</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Lecoq</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Golubeva</surname> <given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis</article-title>. <source>PloS One</source>. <year>2009</year>;<volume>4</volume>(<issue>11</issue>):<fpage>e7954</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0007954" xlink:type="simple">10.1371/journal.pone.0007954</ext-link></comment> <object-id pub-id-type="pmid">19956770</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">Hong Kong Chest Service Tuberculosis Research Centre MBMRC</collab>. <article-title>A Controlled Clinical Comparison of 6 and 8 Months of Antituberculosis Chemotherapy in the Treatment of Patients with Silicotuberculosis in Hong Kong</article-title>. <source>Am Rev Resp Dis</source>. <year>1991</year>;<volume>143</volume>(<issue>2</issue>):<fpage>262</fpage>–<lpage>7</lpage>. <object-id pub-id-type="pmid">1990938</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>YH</given-names></name>, <name name-style="western"><surname>Suh</surname> <given-names>GY</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>MP</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kwon</surname> <given-names>OJ</given-names></name>, <name name-style="western"><surname>Lim</surname> <given-names>SY</given-names></name>, <etal>et al</etal>. <article-title>Treatment of isoniazid-resistant pulmonary tuberculosis</article-title>. <source>BMC Infect Dis</source> <year>2008</year>;<volume>8</volume>:<fpage>6</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2334-8-6" xlink:type="simple">10.1186/1471-2334-8-6</ext-link></comment> <object-id pub-id-type="pmid">18211720</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Temple</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Ayakaka</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Ogwang</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nabanjja</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kayes</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nakubulwa</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda</article-title>. <source>Clin Infect Dis</source> <year>2008</year>;<volume>47</volume>(<issue>9</issue>):<fpage>1126</fpage>–<lpage>34</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/592252" xlink:type="simple">10.1086/592252</ext-link></comment> <object-id pub-id-type="pmid">18808360</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yoshiyama</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Yanai</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rhiengtong</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Palittapongarnpim</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Nampaisan</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Supawitkul</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes</article-title>. <source>Int J Tuberc Lung Dis</source> <year>2004</year>;<volume>8</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">14974743</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">Algerian Working Group/British MRC</collab>. <article-title>Short-course chemotherapy for pulmonary tuberculosis under routine programme conditions: a comparison of regimens at 28 and 36 weeks duration in Algeria</article-title>. <source>Tubercle</source>. <year>1991</year>;<volume>72</volume>:<fpage>88</fpage>–<lpage>100</lpage>. <object-id pub-id-type="pmid">1949222</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lienhardt</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Cook</surname> <given-names>SV</given-names></name>, <name name-style="western"><surname>Burgos</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Yorke-Edwards</surname> <given-names>V</given-names></name>, <name name-style="western"><surname>Rigouts</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Anyo</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>305</volume>(<issue>14</issue>):<fpage>1415</fpage>–<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.2011.436" xlink:type="simple">10.1001/jama.2011.436</ext-link></comment> <object-id pub-id-type="pmid">21486974</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">Tuberculosis Research Centre ICoMR</collab>. <article-title>A controlled clinical trial of oral short course regimens in the treatment of sputum positive pulmonary tuberculosis</article-title>. <source>Int J Tuberc Lung Dis</source>.<volume>1</volume>(<issue>6</issue>):<fpage>509</fpage>–<lpage>17</lpage>. <object-id pub-id-type="pmid">9487448</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aung</surname> <given-names>KJM</given-names></name>, <name name-style="western"><surname>Declercq</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Ali</surname> <given-names>MA</given-names></name>, <name name-style="western"><surname>Naha</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Roy</surname> <given-names>SCD</given-names></name>, <name name-style="western"><surname>Taleb</surname> <given-names>MA</given-names></name>, <etal>et al</etal>. <article-title>Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout</article-title>. <source>Int J Tuberc Lung Dis</source> <year>2012</year>;<volume>16</volume>(<issue>4</issue>):<fpage>455</fpage>–<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.5588/ijtld.11.0216" xlink:type="simple">10.5588/ijtld.11.0216</ext-link></comment> <object-id pub-id-type="pmid">22640511</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cox</surname> <given-names>HS</given-names></name>, <name name-style="western"><surname>Niemann</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ismailov</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Doshetov</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Orozco</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Blok</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance</article-title>. <source>Clin Infect Dis</source> <year>2007</year>;<volume>44</volume>(<issue>11</issue>):<fpage>1421</fpage>–<lpage>7</lpage>. <object-id pub-id-type="pmid">17479936</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>El Sahly</surname> <given-names>HM</given-names></name>, <name name-style="western"><surname>Teeter</surname> <given-names>LD</given-names></name>, <name name-style="western"><surname>Pawlak</surname> <given-names>RR</given-names></name>, <name name-style="western"><surname>Musser</surname> <given-names>JM</given-names></name>, <name name-style="western"><surname>Graviss</surname> <given-names>EA</given-names></name>. <article-title>Drug-resistant tuberculosis: a disease of target populations in Houston, Texas</article-title>. <source>J Infect</source> <year>2006</year>;<volume>53</volume>(1532–2742; 0163–4453; <issue>1</issue>):<fpage>5</fpage>–<lpage>11</lpage>. <object-id pub-id-type="pmid">16310855</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Murray</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Sonnenberg</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Shearer</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Godfrey-Faussett</surname> <given-names>P</given-names></name>. <article-title>Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection</article-title>. <source>S Afr Med J</source> <year>2000</year>;<volume>90</volume>(<issue>4</issue>):<fpage>381</fpage>–<lpage>6</lpage>. <object-id pub-id-type="pmid">10957924</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nettles</surname> <given-names>RE</given-names></name>, <name name-style="western"><surname>Mazo</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Alwood</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Gachuhi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Maltas</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Wendel</surname> <given-names>K</given-names></name>, <etal>et al</etal>. <article-title>Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use</article-title>. <source>Clin Infect Dis</source> <year>2004</year>;<volume>38</volume>(<issue>5</issue>):<fpage>731</fpage>–<lpage>6</lpage>. <object-id pub-id-type="pmid">14986259</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pasipanodya</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>McIlleron</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Burger</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Wash</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Gumbo</surname> <given-names>T</given-names></name>. <article-title>Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes</article-title>. <source>J Infect Dis</source> <year>2013</year>;<volume>208</volume>(<issue>9</issue>):<fpage>1464</fpage>–<lpage>73</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/infdis/jit352" xlink:type="simple">10.1093/infdis/jit352</ext-link></comment> <object-id pub-id-type="pmid">23901086</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chien</surname> <given-names>JY</given-names></name>, <name name-style="western"><surname>Lai</surname> <given-names>CC</given-names></name>, <name name-style="western"><surname>Tan</surname> <given-names>CK</given-names></name>, <name name-style="western"><surname>Chien</surname> <given-names>ST</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>CJ</given-names></name>, <name name-style="western"><surname>Hsueh</surname> <given-names>PR</given-names></name>. <article-title>Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan</article-title>. <source>J Antimicrob Chemother</source>. <year>2013</year>; <volume>68</volume>(<issue>8</issue>):<fpage>1910</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dkt103" xlink:type="simple">10.1093/jac/dkt103</ext-link></comment> <object-id pub-id-type="pmid">23580558</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Driver</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Munsiff</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kundamal</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Osahan</surname> <given-names>SS</given-names></name>. <article-title>Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City</article-title>. <source>Clin Infect Dis</source> <year>2001</year>;<volume>33</volume>(<issue>10</issue>):<fpage>1762</fpage>–<lpage>9</lpage>. <object-id pub-id-type="pmid">11595988</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gelmanova</surname> <given-names>IY</given-names></name>, <name name-style="western"><surname>Keshavjee</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Golubchikova</surname> <given-names>VT</given-names></name>, <name name-style="western"><surname>Berezina</surname> <given-names>VI</given-names></name>, <name name-style="western"><surname>Strelis</surname> <given-names>AK</given-names></name>, <name name-style="western"><surname>Yanova</surname> <given-names>GV</given-names></name>, <etal>et al</etal>. <article-title>Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance</article-title>. <source>Bull World Health Organ</source> <year>2007</year>;<volume>85</volume>(<issue>9</issue>):<fpage>703</fpage>–<lpage>11</lpage>. <object-id pub-id-type="pmid">18026627</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jasmer</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Seaman</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Gonzalez</surname> <given-names>LC</given-names></name>, <name name-style="western"><surname>Kawamura</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Osmond</surname> <given-names>DH</given-names></name>, <name name-style="western"><surname>Daley</surname> <given-names>CL</given-names></name>. <article-title>Tuberculosis treatment outcomes: directly observed therapy compared with self-administered therapy</article-title>. <source>Am J Respir Crit Care Med</source> <year>2004</year>;<volume>170</volume>(1073–449; 1073–449; <issue>5</issue>):<fpage>561</fpage>–<lpage>6</lpage>. <object-id pub-id-type="pmid">15184210</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Munsiff</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Driver</surname> <given-names>CR</given-names></name>, <name name-style="western"><surname>Sackoff</surname> <given-names>J</given-names></name>. <article-title>Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997–2000</article-title>. <source>Clin Infect Dis</source> <year>2005</year>;<volume>41</volume>(<issue>1</issue>):<fpage>83</fpage>–<lpage>91</lpage>. <object-id pub-id-type="pmid">15937767</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Moulding</surname> <given-names>TS</given-names></name>, <name name-style="western"><surname>Le</surname> <given-names>HQ</given-names></name>, <name name-style="western"><surname>Rikleen</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Davidson</surname> <given-names>P</given-names></name>. <article-title>Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin</article-title>. <source>Int J Tuberc Lung Dis</source> <year>2004</year>;<volume>8</volume>(<issue>6</issue>):<fpage>743</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">15182145</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Porco</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Flood</surname> <given-names>JM</given-names></name>. <article-title>Anti-tuberculosis drug resistance acquired during treatment: an analysis of cases reported in California, 1994–2006</article-title>. <source>Clin Infect Dis</source> <volume>56</volume>(<issue>6</issue>):<fpage>761</fpage>–<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/cis989" xlink:type="simple">10.1093/cid/cis989</ext-link></comment> <object-id pub-id-type="pmid">23223590</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Quy</surname> <given-names>HT</given-names></name>, <name name-style="western"><surname>Lan</surname> <given-names>NT</given-names></name>, <name name-style="western"><surname>Borgdorff</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Grosset</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Linh</surname> <given-names>PD</given-names></name>, <name name-style="western"><surname>Tung</surname> <given-names>LB</given-names></name>, <etal>et al</etal>. <article-title>Drug resistance among failure and relapse cases of tuberculosis: is the standard re-treatment regimen adequate?</article-title> <source>Int J Tuberc Lung Dis</source> <year>2003</year>;<volume>7</volume>(<issue>7</issue>):<fpage>631</fpage>–<lpage>6</lpage>. <object-id pub-id-type="pmid">12870683</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Seung</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Gelmanova</surname> <given-names>IE</given-names></name>, <name name-style="western"><surname>Peremitin</surname> <given-names>GG</given-names></name>, <name name-style="western"><surname>Golubchikova</surname> <given-names>VT</given-names></name>, <name name-style="western"><surname>Pavlova</surname> <given-names>VE</given-names></name>, <name name-style="western"><surname>Sirotkina</surname> <given-names>OB</given-names></name>, <etal>et al</etal>. <article-title>The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis</article-title>. <source>Clin Infect Dis</source> <year>2004</year>;<volume>39</volume>(<issue>9</issue>):<fpage>1321</fpage>–<lpage>8</lpage>. <object-id pub-id-type="pmid">15494909</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Spellman</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Matty</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Weis</surname> <given-names>SE</given-names></name>. <article-title>A survey of drug-resistant <italic>Mycobacterium tuberculosis</italic> and its relationship to HIV infection</article-title>. <source>AIDS</source> <year>1998</year>;<volume>12</volume>(<issue>2</issue>):<fpage>191</fpage>–<lpage>5</lpage>. <object-id pub-id-type="pmid">9468368</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weis</surname> <given-names>SE</given-names></name>, <name name-style="western"><surname>Slocum</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Blais</surname> <given-names>FX</given-names></name>, <name name-style="western"><surname>King</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Nunn</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Matney</surname> <given-names>GB</given-names></name>, <etal>et al</etal>. <article-title>The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis</article-title>. <source>N Engl J Med</source> <year>1994</year>;<volume>330</volume>(0028–4793; 0028–4793; <issue>17</issue>):<fpage>1179</fpage>–<lpage>84</lpage>. <object-id pub-id-type="pmid">8139628</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yuen</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Kurbatova</surname> <given-names>EV</given-names></name>, <name name-style="western"><surname>Click</surname> <given-names>ES</given-names></name>, <name name-style="western"><surname>Cavanaugh</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Cegielski</surname> <given-names>JP</given-names></name>. <article-title>3871645; Association between <italic>Mycobacterium tuberculosis</italic> Complex Phylogenetic Lineage and Acquired Drug Resistance</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>12</issue>):<fpage>e83006</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0083006" xlink:type="simple">10.1371/journal.pone.0083006</ext-link></comment> <object-id pub-id-type="pmid">24376623</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bradford</surname> <given-names>WZ</given-names></name>, <name name-style="western"><surname>Martin</surname> <given-names>JN</given-names></name>, <name name-style="western"><surname>Reingold</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Schecter</surname> <given-names>GF</given-names></name>, <name name-style="western"><surname>Hopewell</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Small</surname> <given-names>PM</given-names></name>. <article-title>The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA</article-title>. <source>Lancet</source>. <year>1996</year>;<volume>348</volume> (<issue>9032</issue>):<fpage>928</fpage>–<lpage>31</lpage>. <object-id pub-id-type="pmid">8843813</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Munsiff</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Joseph</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ebrahimzadeh</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Frieden</surname> <given-names>TR</given-names></name>. <article-title>Rifampin-monoresistant tuberculosis in New York City, 1993–1994</article-title>. <source>Clin Infect Dis</source> <year>1997</year>;<volume>25</volume>(<issue>6</issue>):<fpage>1465</fpage>–<lpage>7</lpage>. <object-id pub-id-type="pmid">9431396</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Weiner</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Benator</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Burman</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Peloquin</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Khan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Vernon</surname> <given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis</article-title>. <source>Clin Infect Dis</source> <year>2005</year>;<volume>40</volume>(<issue>10</issue>):<fpage>1481</fpage>–<lpage>91</lpage>. <object-id pub-id-type="pmid">15844071</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lew</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Pai</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Oxlade</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Martin</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Menzies</surname> <given-names>D</given-names></name>. <article-title>Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis</article-title>. <source>Ann Intern Med</source> <year>2008</year>;<volume>149</volume>(<issue>2</issue>):<fpage>123</fpage>–<lpage>34</lpage>. <object-id pub-id-type="pmid">18626051</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Menzies</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Benedetti</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Paydar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Royce</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pai</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Burman</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: A systematic review and meta-analysis</article-title>. <source>PLoS Med</source> <year>2009</year> <volume>6</volume> (<issue>9</issue>).:<fpage>e1000150</fpage>. <object-id pub-id-type="pmid">20101802</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jacobson</surname> <given-names>KR</given-names></name>, <name name-style="western"><surname>Theron</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Victor</surname> <given-names>TC</given-names></name>, <name name-style="western"><surname>Streicher</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Warren</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Murray</surname> <given-names>MB</given-names></name>. <article-title>Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa</article-title>. <source>Clin Infect Dis</source> <year>2011</year>;<volume>53</volume>(<issue>4</issue>):<fpage>369</fpage>–<lpage>72</lpage> <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/cir406" xlink:type="simple">10.1093/cid/cir406</ext-link></comment> <object-id pub-id-type="pmid">21810750</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref043"><label>43</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Comas</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Borrell</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Roetzer</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Rose</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Malla</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Kato-Maeda</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Whole-genome sequencing of rifampicin-resistant <italic>Mycobacterium tuberculosis</italic> strains identifies compensatory mutations in RNA polymerase genes</article-title>. <source>Nature Genetics</source>. <year>2011</year>;<volume>44</volume>(<issue>1</issue>):<fpage>106</fpage>–<lpage>10</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.1038" xlink:type="simple">10.1038/ng.1038</ext-link></comment> <object-id pub-id-type="pmid">22179134</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fenner</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bodmer</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Furrer</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ballif</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Battegay</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis</article-title>. <source>PLoS Genetics</source>. <year>2013</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e1003318</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pgen.1003318" xlink:type="simple">10.1371/journal.pgen.1003318</ext-link></comment> <object-id pub-id-type="pmid">23505379</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref045"><label>45</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Strauss</surname> <given-names>OJ</given-names></name>, <name name-style="western"><surname>Warren</surname> <given-names>RM</given-names></name>, <name name-style="western"><surname>Jordaan</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Streicher</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Hanekom</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Falmer</surname> <given-names>AA</given-names></name>, <etal>et al</etal>. <article-title>Spread of a low-fitness drug-resistant <italic>Mycobacterium tuberculosis</italic> strain in a setting of high human immunodeficiency virus prevalence</article-title>. <source>J Clin Microbiol</source> <year>2008</year>;<volume>46</volume>(<issue>4</issue>):<fpage>1514</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JCM.01938-07" xlink:type="simple">10.1128/JCM.01938-07</ext-link></comment> <object-id pub-id-type="pmid">18272712</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref046"><label>46</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chideya</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Winston</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Peloquin</surname> <given-names>CA</given-names></name>, <name name-style="western"><surname>Bradford</surname> <given-names>WZ</given-names></name>, <name name-style="western"><surname>Hopewell</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Wells</surname> <given-names>CD</given-names></name>, <etal>et al</etal>. <article-title>Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana</article-title>. <source>Clin Infect Dis</source> <year>2009</year>;<volume>48</volume>(<issue>12</issue>):<fpage>1685</fpage>–<lpage>94</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/599040" xlink:type="simple">10.1086/599040</ext-link></comment> <object-id pub-id-type="pmid">19432554</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref047"><label>47</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gumbo</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Louie</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Deziel</surname> <given-names>MR</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Parsons</surname> <given-names>LM</given-names></name>, <name name-style="western"><surname>Salfinger</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Concentration-dependent <italic>Mycobacterium tuberculosis</italic> killing and prevention of resistance by rifampin</article-title>. <source>Antimicrob Agents and Chemother</source> <year>2007</year>;<volume>51</volume>(<issue>11</issue>):<fpage>3781</fpage>–<lpage>8</lpage>.</mixed-citation></ref>
<ref id="pone.0139017.ref048"><label>48</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pasipanodya</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Gumbo</surname> <given-names>T</given-names></name>. <article-title>An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future</article-title>. <source>Antimicrob Agents and Chemother</source> <year>2011</year>;<volume>55</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>34</lpage>.</mixed-citation></ref>
<ref id="pone.0139017.ref049"><label>49</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pasipanodya</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Srivastava</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gumbo</surname> <given-names>T</given-names></name>. <article-title>Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy</article-title>. <source>Clin Infect Dis</source> <year>2012</year>;<volume>55</volume>(<issue>2</issue>):<fpage>169</fpage>–<lpage>77</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/cis353" xlink:type="simple">10.1093/cid/cis353</ext-link></comment> <object-id pub-id-type="pmid">22467670</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref050"><label>50</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ford</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Shah</surname> <given-names>RR</given-names></name>, <name name-style="western"><surname>Maeda</surname> <given-names>MK</given-names></name>, <name name-style="western"><surname>Gagneux</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Murray</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Cohen</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title><italic>Mycobacterium tuberculosis</italic> mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis</article-title>. <source>Nat Genet</source> <year>2013</year>;<volume>45</volume>(<issue>7</issue>):<fpage>784</fpage>–<lpage>90</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ng.2656" xlink:type="simple">10.1038/ng.2656</ext-link></comment> <object-id pub-id-type="pmid">23749189</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref051"><label>51</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Borrell</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Gagneux</surname> <given-names>S</given-names></name>. <article-title>Strain diversity, epistasis and the evolution of drug resistance in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Clin Microbiol Infect</source> <year>2011</year>;<volume>17</volume>(1469–0691; 1198–743; <issue>6</issue>):<fpage>815</fpage>–<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1469-0691.2011.03556.x" xlink:type="simple">10.1111/j.1469-0691.2011.03556.x</ext-link></comment> <object-id pub-id-type="pmid">21682802</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref052"><label>52</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pasipanodya</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Gumbo</surname> <given-names>T</given-names></name>. <article-title>A meta-analysis of self-administered versus directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients</article-title>. <source>Clin Infect Dis</source> <year>2013</year> <volume>57</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/cit167" xlink:type="simple">10.1093/cid/cit167</ext-link></comment> <object-id pub-id-type="pmid">23487389</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref053"><label>53</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ioannidis</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Patsopoulos</surname> <given-names>NA</given-names></name>, <name name-style="western"><surname>Evangelou</surname> <given-names>E</given-names></name>. <article-title>Uncertainty in heterogeneity estimates in meta-analyses</article-title>. <source>BMJ</source> <year>2007</year> 3;<volume>335</volume>(<issue>7626</issue>):<fpage>914</fpage>–<lpage>6</lpage>. <object-id pub-id-type="pmid">17974687</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref054"><label>54</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kontopantelis</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Springate</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Reeves</surname> <given-names>D</given-names></name>. <article-title>A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses</article-title>. <source>PLoS One</source> <year>2013</year> <source>Jul 26</source>;<volume>8</volume>(<issue>7</issue>):<fpage>e69930</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0069930" xlink:type="simple">10.1371/journal.pone.0069930</ext-link></comment> <object-id pub-id-type="pmid">23922860</object-id></mixed-citation></ref>
<ref id="pone.0139017.ref055"><label>55</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Albanna</surname> <given-names>AS</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>BM</given-names></name>, <name name-style="western"><surname>Cowan</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Menzies</surname> <given-names>D</given-names></name>. <article-title>Fixed dose combination anti-tuberculosis therapy: a systematic review and meta-analysis</article-title>. <source>Eur Resp J</source> <year>2013</year> <volume>42</volume> (<issue>3</issue>):<fpage>721</fpage>–<lpage>322</lpage>.</mixed-citation></ref>
<ref id="pone.0139017.ref056"><label>56</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Menzies</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Benedetti</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Paydar</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Martin</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Royce</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Pai</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis</article-title>. <source>PLoS Med</source>. <year>2009</year>;<volume>6</volume>(<issue>9</issue>):<fpage>e1000146</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pmed.1000146" xlink:type="simple">10.1371/journal.pmed.1000146</ext-link></comment> <object-id pub-id-type="pmid">19753109</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>